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Chronic inflammation in the brain results in the development of several CNS
diseases, including Alzheimer’s and Parkinson’s diseases, multiple sclerosis, and tumors.
IL-1, a pro-inflammatory cytokine released by activated microglia and astrocytes, instigates
the expression of factors promoting the progression of these CNS disorders, including
cytokines, chemokines, and components of matrix remodeling systems, such as the
plasminogen activator system. IL-1 also increases the mRNA expression and activity of
SphK, the enzyme that phosphorylates Sph to form S1P, a bio-active sphingolipid. This
vi

vii
thesis demonstrates that IL-1 and S1P enhance the mRNA and protein expression of PAI-1
and uPAR, two key components of the plasminogen activator system, in glioblastoma cells.
The S1P-induced mRNA expression of PAI-1 and uPAR is mediated by the S1P2 receptor,
and requires Rho-kinase and MEK1. However, IL-1 regulation of PAI-1 and uPAR mRNA
expression is independent of SphK, and thus S1P. IL-1- and S1P-induced mRNA expression
of PAI-1 and uPAR results in the increased in vitro invasion of glioblastoma cells. Since
significant amounts of IL-1 are secreted from gliomas, and it increases the production of S1P
via inciting the activity and mRNA expression of SphK, we propose a mechanism by which
S1P and IL-1 influence the invasion of glioblastoma cells by increasing the mRNA and
protein expression of uPAR and PAI-1.
IL-1 and S1P also influence the mRNA expression of chemokines implicated in the
development and progression of multiple sclerosis, namely IP-10 and RANTES, in primary
human astrocytes. IP-10 and RANTES attract T cells, which are the major pathological
cause of multiple sclerosis. This thesis demonstrates a novel mechanism by which S1P
significantly inhibits the IL-1-induced mRNA expression of these chemokines. The
mechanism by which S1P reduces IL-1-induced IP-10 and RANTES mRNA expression
involves the prolonged hyperphosphorylation of TAK1, as well as the inhibition of IL-1stimulated IFNβ production and the phosphorylation of STAT1 and STAT2.
In summary, this dissertation describes the mechanisms by which S1P and IL-1
control the mRNA expression of two chemokines associated with multiple sclerosis, and the
components of the plasminogen activator system, which are critical for the invasion of
glioblastoma cells; thus, indicating future therapeutic targets for destructive CNS disorders.
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CHAPTER 1
INTRODUCTION
1.1 Inflammation in the Brain
Inflammation is the classic response of the human body to injury and infection. In
most tissues, inflammation is characterized by swelling, redness, pain, and heat. This
characteristic phenotype of inflammation is caused by immune cells, such as macrophages
and leukocytes that invade the inflamed tissue. Once activated, macrophages are the primary
source of cytokines and growth factors, which then influence proliferation, migration,
angiogenesis, etc. in order to repair the affected tissue .
Although the brain was once considered immune deficient, as it lacks a lymphatic
system and is protected by the blood brain barrier (BBB), it is now known that this is not the
case. However, its immune response is unarguably different from that in other tissues. For
example, swelling, which is typical in inflammation, is limited by the cranium and can lead
to intracranial pressure and death. Also, compared to other tissues, leukocyte recruitment is
delayed in the brain. However, once an insult on the brain occurs, pro-inflammatory factors
are rapidly released from microglia (the immune cells of the brain) , and activated microglia
undergo a morphological change from ramified microglia into amoeboid microglia [2].
Activated microglia release a variety of pro-inflammatory and likely cytotoxic factors, which
then stimulate surrounding astrocytes to secrete additional pro-inflammatory cytokines and
chemokines. Cytokines and chemokines are then responsible for the recruitment of
1

2
leukocytes and neutrophils. During acute inflammation this response is controlled, limited,
and successful in repairing the damaged tissue. However, chronic inflammation, which is uncontrolled and sustained inflammation, can often result in tissue damage and necrosis.
Chronic inflammation has been linked to traumatic brain injury, various central
nervous system (CNS) disorders (Alzheimer’s, Multiple Sclerosis, and HIV-1 associated
dementia), and even cancer . In fact, in Alzheimer’s disease, which is characterized by
progressive neuronal damage caused by the neurotoxicity of the β-amyloid peptide, the
microglial reaction to β-amyloid and the plaques can be deleterious to neurons. β-amyloid
peptide recruits and activates microglia , thus leading to the release of neurotoxic factors,
such as NO , TNFα , and superoxide . Activated microglia have also been implicated in the
progression of HIV-associated dementia, as HIV enters the brain via circulating monocytes
and is then collected by microglia . Therefore, the microglia act as a factory for viral
replication, leading to an increase in pro-inflammatory factors and the progression of the
disease. Moreover, activated microglia have been associated with Parkinson’s disease and
Multiple Sclerosis (MS) . Interestingly, viral infection with the Epstein-Barr virus has been
connected to MS, as EBV-infected cells were found in the meninges and perivascular
immune infiltrates of active white matter lesions in almost 100% of the analyzed MS patients
.
Just as chronic inflammation in the brain can lead to various CNS diseases, chronic
inflammation of other tissues present in the body has been shown to stimulate the
progression of several types of cancer. In fact, the tumor microenvironment, which consists
of macrophages, dendritic cells, T cells, and natural killer cells, which all produce and
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secrete a variety of cytokines, reactive oxygen species, serine and cysteine proteases, and
MMPs, has been shown to advance tumor promotion and progression via mouse models of
human cancer . Interestingly, chronic inflammation may be a key factor in transformation, as
infection with Helicobacter pylori is linked to gastrointestinal carcinogenesis; Hepatitis B
infection is associated with hepatocellular carcinoma; cigarette smoking with lung cancer;
Schistosomiasis is connected with bladder carcinoma; alcoholism with pancreatic cancer ;
and inflammatory bowel diseases is strongly correlated with colon carcinogenesis . So while
inflammation is a necessary component of the immune response to clear infection or repair
tissue, if inflammation persists it can become detrimental to the affected tissue and the host,
as it may lead to cancer or various other CNS diseases.

1.2 Interleukin-1
As mentioned previously, the tumor microenvironment, which consists of a variety
of immune cells, contributes to tumor progression by supplying an array of cytokines and
chemokines to neighboring tumor cells. In addition, tumor cells are capable of contributing
to their microenvironment as well. In fact, gliomas, the most common and most malignant of
the primary brain tumors, have been shown secrete substantial amounts of interleukin-1
(IL-1) . IL-1 is the predominant pro-inflammatory cytokine in the brain, is a 17 kilodalton
(kDa) polypeptide, and exists in two isoforms, IL-1α and IL-1β . Although, IL-1α and IL-1β
share 30% sequence homology, bind to the same receptor, and activate the same signaling
pathways, they are expressed and secreted differently . For instance, IL-1α is only located
within the cell, while IL-1β is secreted upon cleavage of pro-IL-1β by caspase-1 . In contrast
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to pro-IL-1β which must be cleaved in order to be active, pro-IL-1α is equally active as its
mature form.
Regardless of the isoform, all known functions of IL-1 are due to the interaction with
their receptor IL-1R . The IL-1R is a member of the Toll-like receptor family, specifically
the TIR (Toll-IL-1 receptor) superfamily . Members of the TIR superfamily contain an
intracellular TIR domain, which can interact with the adaptor protein MyD88 (myeloid
differentiation factor 88) upon stimulation . Downstream signaling from IL-1R also requires
the association of an accessory protein, called IL-1RAcP, in order to activate nuclear factor
kappa B (NF-κB) and the mitogen-activated protein (MAP) kinase pathways, including p38
MAPK, c-jun N-terminal kinase (JNK), and extracellular-signal regulated kinase (ERK1/2) .
Upon stimulation with IL-1, the IL-1RI sequesters the MyD88 adapter molecule ,
which then recruits IRAK4 (IL-1 receptor associated kinase 4), IRAK, and TRAF6 (TNF
receptor associated factor 6). Once this complex is formed, IRAK4 is activated, thus leading
to the hyperphosphorylation of IRAK and the interaction with Pellino 1 . This complex is
then released from the receptor to form and intermediate complex, upon which TAK1
(transforming growth factor β-activated kinase, a MAP3K), TAB2 (TAK1-binding protein
2), and TAB3 all bind and are phosphorylated at the membrane . Once IRAK is ubiquitinated
and degraded, the TRAF6-TAK1-TAB2-TAB3 complex moves from the membrane to the
cytosol. Once in the cytosol, TAK1 becomes phosphorylated, activated, induces IκB kinase
(inhibitor of NF-κB kinase, IKK), which leads to the phosphorylation/degradation of IκBs
(inhibitor of NF-κB) and activation NF-κB (Figure 1.1, ). However, TAK1 is also capable
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of activating p38 and JNK via MKK3/6 and MKK4/7, respectively (Figure 1.1).
Additionally, IL-1 can activate a TAK1-independent and MEKK3-dependent pathway
(Figure 1.1) . The difference in the two pathways is that the TAK1-dependent pathway leads
to IKKα/β phosphorylation and IKKβ activation, and thus classical NF-κB activation via
IκBα phosphorylation and degradation; while the MEKK3-dependent pathway stimulates
IKKγ phosphorylation, IKKα activation, and NF-κB activation by IκBα phosphorylation
and dissociation. Both pathways are controlled at the point of IRAK modification .
Specifically, a point mutation in IRAK from lysine 134 to arginine (K134R) eliminated IL-1induced ubiquitination and degradation, which ablated TAK1-dependent NF-κB activation,
but not MEKK3-dependent activation of NF-κB . Pellino proteins are the E3 ubiquitin
ligases responsible for IRAK ubiquitination, of which there are four (Pellino1, 2, 3a, and 3b).
Pellino 1 and 2 mediated IRAK modification leads to the activation NF-κB, whereas Pellino
3a and 3b leads to JNK activation .

6

Figure 1.1 Model depicting TAK1-dependent and TAK1-independent IL-1 signaling.
IL-1 stimulation results in MyD88 and Tollip recruitment to the IL-1 receptor. Subsequently,
IRAK4, IRAK, and TRAF6 are recruited, which leads to the arrangement of complex I. At
this point, IRAK4 is activated, IRAK is hyperphosphorylated, and this allows for the
interaction of Pellino 1/2 with IRAK4-IRAK-TRAF6 complex (intermediate complex).
IRAK is ubiquitinated at Lys-63, which induces the interaction of the intermediate complex
(Pellino 2-IRAK4-IRAK-TRAF6 with membrane bound TAK1-TAB1-TAB2 (which
completes the formation of complex II). An unknown E3 protein induces the Lys-48
ubiquitination of IRAK, causing the degradation of IRAK, which leads to the translocation
of TRAF6-TAK1-TAB1-TAB2 (complex III) to the cytosol from the membrane. TAK1 is
activated and eventually leads to the activation of NF-κB, JNK, and p38. In contrast the
TAK1-independent pathway involves MEKK3 induction of IKKγ phosphorylation and
IKKα activation, which leads only to the activation of NF-κB.
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Modified from

8
In the healthy adult brain IL-1 and the IL-1R are expressed at very low levels, and
IL-1 is suspected to regulate long-term potentiation, sleep, and memory . However, during
pathological conditions, such as CNS injury and focal cerebral ischemia , levels of IL-1 are
increased substantially. Furthermore, in vitro studies in astrocytes have revealed that IL-1
induces proliferation , astrogliosis , and activates NF-κB, p38, JNK, and ERK1/2 (Reviewed
in ). Additionally, IL-1 stimulation leads to the expression of cytokines, such as IL-6, IL-8,
and TNF-α, chemokines, including MIP-1α, MIP-1β, MCP-1, IP-10, and RANTES (Chapter
3), growth factors, consisting of bFGF, NGF, VEGF, and PDGF, and matrix
metalloproteinases, specifically MMP9 . Moreover, we show that IL-1 can increase two
critical components of the plasminogen activator system (urokinase protease activator
receptor [uPAR] and plasminogen activator inhibitor-1 [PAI-1]) in U373 glioblastoma cells,
thus contributing to their invasive phenotype (Chapter 2).
In addition to its robust acute effects, IL-1 has been involved in chronic CNS
disorders. In the brains’ of patients with Alzheimer’s disease and Down’s syndrome, IL-1β
has been found to increase the supply and processing of the β-amyloid precursor protein, in
addition to the production of other known plaque-associated proteins . Additionally, IL-1
levels were elevated in the lesions of human immunodeficiency virus (HIV)-associated
dementia patients , and in the spinal fluid and demyelinated lesions of multiple sclerosis
patients . These results suggest that IL-1 is critical for both acute and chronic inflammation,
and thus that IL-1 may play a significant role in the progression of many neurological
diseases.
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1.3 Chemokines
Additionally, IL-1, when released from activated microglia, stimulates surrounding
astrocytes to produce and secrete a variety of cytokines (including IL-1) and chemokines.
This triggers leukocytes, which under normal physiological conditions are constantly in the
blood stream surveying the body for signs of injury or infection, to invade the vascular
endothelium and follow the chemotactic gradient of chemokines into the inflamed tissue .
The chemokine family consists of approximately 50 small secreted ligands (8-13 kDa) that
bind to 20 different G-protein-coupled seven-transmembrane receptors . The chemokine
family is divided into two subfamilies, CXC and CC chemokines, based on the absence or
presence of an amino acid between the first two NH2-terminal cysteines . The CXC family of
chemokines is further separated based on whether or not they contain the ELR (Glu-LeuArg) motif. ELR+CXC chemokines (CXCL1-8) are chemotatic for neutrophils and are
angiogenic, while ELR-CXC chemokines (CXCL9-12) attract mononuclear leukocytes and
are angiostatic. For example, over-expression of CXCL10 (IP-10, interferon-γ-inducible
protein-10) in a human lymphoma mouse model, as well as in a human non-small cell lung
cancer SCID mouse model , resulted in spontaneous regression due to deficient angiogenesis
. In contrast, IL-8 (interleukin-8), a member (CXCL8) of the CXC family of chemokines,
attracts neutrophils and is ELR+; thus IL-8 is pro-angiogenic and has been associated with
increased microvessel counts in uterine cervical cancers . Meanwhile, CC chemokines, such
as CCL5 (RANTES, regulated on activation normal T-cell-expressed and secreted), CCL3
(MIP-1α, macrophage

inflammatory

protein-1α),

and

CCL4

(MIP-1β, macrophage

inflammatory protein-1β), attract an array of leukocytes. For instance, RANTES is
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chemotactic for T cells, while CCL2 (MCP-1, monocyte chemoattractant protein-1) attracts
monocytes.
In order for chemokines to exert their effects, they must interact with their receptors.
The chemokine receptors are separated into CXCR1-6, CCR1-11, CX3CR1, and XCR1.
Some of the receptors are highly promiscuous, while others have a high specificity for their
ligands. Examples of monogamous receptor-ligand interactions are CXCL12 binding to the
CXCR4 receptor, fractalkine binding to the CX3CR1 receptor, and lymphotactin binding to
the XCR1 receptor. In contrast, IP-10, CXCL9, and CXCL11 can all interact with the
CXCR3 receptor. However, it is not just the receptors that are promiscuous in this system, as
some ligands can also interact with multiple receptors. For instance, RANTES can bind to
CCR1, CCR3, or CCR5 . For a complete list of the chemokine ligands and their receptors,
please see Table 1.1 (Modified from ).
Chemokines are involved in a multitude of processes, including angiogenesis,
hematopoiesis, and tumor progression and metastasis . Indeed, the chemokine CXCL12 and
its receptor CXCR4, as well as CXCL1, are upregulated in primary brain tumors, such as
glioblastoma, astrocytoma, and medulloblastomas . Moreover, this chemokine and its
receptor have been shown to be crucial for the development of the CNS. Specifically,
CXCR4 signaling is necessary for neuronal precursor migration, axon guidance, and
maintenance of neural progenitor cells . Meanwhile, CXCL12 regulates neurotoxicity,
neurotransmission, and neuroglial interactions . Other chemokines, such as RANTES and
MCP-1, were
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Table 1.1 Table of Chemokines and their respective receptors. Chemokines are divided
into two classes, CXC and CC. They are listed along with their receptors, alternative names,
as well as the cell types they attract. Tm, memory T cells; B, B cells; actT, activated T cell;
Bs, basophil; T, resting T cell; Eo, eosinophil; NK, natural killer cells; Mo, monocyte; PMN,
neutrophils; mDC, mature dendritic cells; iDC, immature dendritic cells.
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Systematic Name
CXC Chemokines

Functional Name

Responding Cell

Known Receptor(s)

CXCL1
CXCL2
CXCL3
CXCL4
CXCL5
CXCL6
CXCL7
CXCL8
CXCL9
CXCL10
CXCL11
CXCL12
CXCL13
CXCL14
CXCL15
CXCL16
CXCL17
CC Chemokines
CCL1
CCL2

Groα
Groβ
Groγ
PF4
ENA-78
GCP-2
NAP-1
IL-8
MIG
IP-10
I-TAC
SDF-1α/β
BLC, BCA-1
BRAK, Bolekine
Human unknown

PMN
PMN
PMN
Fibroblast
PMN
PMN
PMN
PMN
actT(TH1), NK
actT(TH1), NK
actT(TH1), NK
All cell types
B
cAMP activated Mo
PMN
actT

CXCR2>CXCR1
CXCR2
CXCR2

I-309
MCP-1

iDC, actT (TH2)
Bs, Mo, actT, NK,

CCR8
CCR2

CCL3

MIP-1α

iDC
Eo, Mo, actT, NK,

CCR1. CCR5

CCL3L1
CCL4

LD78β
MIP-1β

CXCR2
CXCR1, CXCR2
CXCR1. CXCR2
CXCR1, CXCR2
CXCR3
CXCR3
CXCR3
CXCR4
CXCR5

CXCR6

DMC

iDC
Mo, actT,(TH1), NK,

CCR5

iDC
CCL4L1
CCL5

AT744.2
RANTES

Eo, Bs, Mo, actT,

CCR1, CCR3, CCR5

CCL6
CCL7

Human unknown
MCP-3

NK, iDC
Mo
Eo, Bs, Mo, actT,

CCR1, CCR2, CCR3
CCR1, CCR2, CCR3
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CCL8

MCP-2

NK, iDC
Bs, Mo, actT, NK,

CCL9/10
CCL11

Human unknown
Eotaxin

iDC
PMN, actT
Eo, Bs, actT(TH2),

CCR3, CCR5
CCR1
CCR3

Human unknown

iDC
Bs, Mo, actT, NK,

CCR2

CCL13
CCL14
CCL15
CCL16
CCL17
CCL18
CCL19
CCL20
CCL21
CCL22
CCL23
CCL24

MCP-4
HCC-1
HCC-2
HCC-4 LEC
TARC
PARC
MIP3β, ELC
MIP3α, LARC
SLC
MDC
MPIF-1
Eotaxin 2

iDC
Bs, Mo, actT, NK
Eo, Mo
PMN, Eo, Mo
Mo, actT(TH1)
actT(TH2)
T, iDC
T, actT, mDC
Tm, B, iDC
T, actT, mDC
actT(TH2), iDC
PMN, Mo, T
Eo, Bs, actT(TH2),

CCL25
CCL26

TECK
Eotaxin 3

iDC
Thymocytes, T
Eo, Bs, actT(TH2),

CCR9
CCR3

CTACK, ILC
MEC

iDC
act
act

CCR10
CCR10

Lymphotaxin
SCM-1β
Fractalkine

T
T
Mo, actT, NK

XCR1
XCR1
CX3CR1

CCL12

CCL27
CCL28
Other Classes
XCL1
XCL2
CX3CL1
Modified from

CCR1, CCR2,

CCR1, CCR2, CCR3
CCR1
CCR1, CCR3
CCR1
CCR4
CCR7
CCR6
CCR7
CCR4
CCR1
CCR3
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discovered to increase the migration and differentiation of mouse embryonic dorsal root
ganglia cells . Additionally, IL-8 (CXCL8) and GROα control fast synaptic transmission, as
well as long-term synaptic plasticity of the cerebellum .
In contrast, during inflammatory diseases of the CNS, chemokines play a much
different role. Specifically, they play a significant role in leukocyte trafficking, which is
responsible for the pathology of the vast majority of CNS diseases. For instance, increased
levels of IP-10 have been found in the cerebrospinal fluid of patients with multiple sclerosis ,
as well as in patients with HIV-associated dementia , where IP-10 may also act as a
neurotoxin . Moreover, IP-10 expression is elevated after ischemia and brain injury .
Interestingly, RANTES has also been linked to the progression of multiple sclerosis , and its
expression has been inversely correlated with the progression of HIV-1 diseases . More
importantly, IL-1 signaling is a major regulator of these chemokines in human astrocytes ,
and it is for these reasons that these specific chemokines are further discussed in Chapter 3.

1.4 Sphingosine 1-phosphate
Interestingly, IL-1 is also capable of inducing sphingosine kinase (SphK) activation
and expression , which is the enzyme responsible for producing sphingosine 1-phosphate
(S1P) from sphingosine (Sph). There are two isoforms of SphK, SphK1 and SphK2. Their
substrate Sph, which has been shown to be involved in cell cycle arrest and apoptosis , is
converted into S1P via phosphorylation on the 1-OH. In contrast to Sph, S1P has been
implicated in cell proliferation, survival, migration, angiogenesis, and differentiation . Thus,
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the balance of these metabolites, also known as the sphingolipid rheostat, is decisive in
determining cell fate .
S1P can act both intracellularly as a second messenger, and extracellularly, in an
autocrine/paracrine manner, by binding to its five transmembrane G-protein coupled
receptors (S1P1-5) . The individual S1P receptors can couple to a distinct group of G proteins,
with varying affinities for different affecter molecules, which can lead to the activation of
mitogen-actvated protein kinase (MAPK/ERK), phospholipase C (PLC), PI3K, Rac, Rho,
and JNK (Reviewed in ). Thus, depending on the receptor expressed in a given cell type, S1P
binding can activate various pathways with often opposing functions. For instance, the S1P1
and S1P3 receptors have been shown to increase endothelial cell migration, while the S1P2
receptor has been shown to inhibit endothelial and glioma cell migration . Conversely, the
S1P2 receptor has recently been shown to increase the invasion of glioma cells . Although
there is a multitude of information known about the extracellular signaling of S1P, it has also
been established that intracellular S1P can increase DNA synthesis, and regulate apoptosis ,
differentiation , calcium mobilization , DNA synthesis , and inflammatory responses .
However, the mechanism and the intracellular targets of S1P signaling are still unknown.
S1P is abundantly stored in blood platelets, and can be found in the blood at a
concentration of 0.4 to 1.5 µM ; therefore, it seems logical that S1P would play an important
role in angiogenesis. In fact, early studies in human umbilical vein endothelial cells
(HUVEC) demonstrated that in response to S1P, vascular endothelial cells migrated and
subsequently morphed into capillary networks . More recently, it was shown that the binding
of S1P to the S1P1 receptor increases the production of the pro-angiogenic growth factor,
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VEGF . Moreover, S1P seems to be important in neural and vascular development, as
SphK1/SphK2 double-knockout mice (which are deficient in S1P) have severe
abnormalitites in neurogenesis, neural tube closure, and angiogenesis, thus is embryonic
lethal . Other functions in the brain include, regulating neural stem cell or progenitor
migration toward the site of injury , inducing mouse embryonic astrocyte proliferation ,
acting as a neurotrophin-3 (NT-3) mediator of oligodendrocyte progenitor survival , and
increasing the expression of glial cell line-derived neurotrophic factor (GDNF) to promote
astrocyte proliferation .
Since S1P is pro-angiogeneic and anti-apoptotic, it is not surprising that S1P plays a
significant role in cancer growth and progression. In fact, SphK1, and thus S1P, has been
shown to be up-regulated in a variety of cancers . Recently, it was shown that a monoclonal
antibody with a high affinity and specificity for S1P can slow tumor progression and related
angiogenesis in several human cancer models, including lung, colon, breast, melanoma, and
ovarian cancers . Moreover, the S1P receptor antagonist FTY720-P, when interacting with
S1P receptors (all except S1P2), potently reduces S1P induced angiogenesis in corneal
models, and reduced primary tumor and metastatic tumor growth in a melanoma mouse
model . Conversely, S1P was shown to increase the chemotactic migration and invasion of
esophageal adenocarcinoma cells and OVCAR3 ovarian cancer cells , as well as the in vitro
invasion of U373 glioblastoma cells (Chapter 2). Moreover, increased levels of expression of
SphK1, and therefore S1P, have been correlated to decreased survival of glioblastoma
patients . Since activation of SphK1 is an important step in the stimulation of the
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plasminogen activator system in response to growth factors, such as EGF, we studied the
effects of S1P on the plasminogen activator system (Chapter 2).

1.5 Plasminogen Activator System
Glioblastoma multiforme (GBM) is one of the most common and most malignant
tumors of the central nervous system . Their invasive phenotype is partially due to the
degradation of the extracellular matrix (ECM). The degradation of the ECM requires the
activation of proteinases and the suppression of their inhibitors. ECM degradation typically
involves two proteolytic systems: the plasminogen activator system (PAS), which controls
the activation of plasmin from inactive plasminogen, and the matrix metalloproteinases and
their inhibitors .
In the brain, microglia are responsible for the production of inactive plasminogen,
and astrocytes and glioma cells supply the components of the PAS, which produce active
plasmin from plasminogen. Plasmin, which is a serine protease with a broad range of
specificity, is activated by tissue type plasminogen activator (tPA) and urokinase-type
plasminogen activator (uPA) . tPA is mainly involved in the dissolution of fibrin clots;
whereas uPA, upon binding to its cell surface receptor (uPAR), has its own protease activity,
and is important for localized ECM degradation that is necessary for cell migration and
invasion . Despite their different functions, both tPA and uPA are regulated by their specific
inhibitors: plasminogen activator inhibitor-1 (PAI-1), PAI-2, and protease nexin (PAI-3).
PAI-1 and PAI-2 are the main inhibitors of the PAS, and they are most likely regulated
differently since PAI-1 is a secreted protein and PAI-2 is mainly found in the cytoplasm .
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When uPA binds to uPAR, it leads to the enhancement of plasmin production, the
localization of proteolytic activity to the cell surface, and the activation of several signaling
pathways via uPAR. Since uPAR lacks transmembrane and cytosolic domains, it must
interact with vitronectin and integrins to activate signaling pathways . When PAI-1 is
present, it binds to the uPA/uPAR/integrin complex, this complex is internalized, uPA and
PAI-1 are degraded, and uPAR is recycled back to the cell surface. Once the
uPA/uPAR/integrin complex is internalized, the cell is no longer attached to the ECM via the
uPA/uPAR/integrin complex, and the cell is free to migrate. Therefore, while PAI-1 inhibits
uPA protease activity, it may be important for cell detachment. Interestingly, increased
levels of PAI-1 are indicative of a poor prognosis for survival in patients afflicted with
several types of cancer, including breast, colon, and neuroblastoma . Moreover, uPA was
recently shown to be up-regulated in meningioma cells in response to radiation, and that this
lead to increased tumor invasion, migration, and angiogenesis in vivo . Moreover, downregulation of uPA and uPAR expression results in significantly decreased tumor invasion,
migration, and angiogenesis in meningioma cells. Similarly, other studies have shown that
neutralizing antibodies to uPA or uPAR , antisense oligonucleotides , and small molecules
that target uPA or uPAR may be important therapeutic targets to suppress tumor growth,
invasion, and metastasis. Therefore, since these components of the PAS seem to be so
important for tumor invasion and metastasis, we examined the regulation of the PAS in
glioblastoma multiforme, which is the most invasive primary brain tumor (Chapter 2).

1.6 Summary
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Chronic inflammation plays a pivotal role in disease progression, as it provides a
constant supply of pro-inflammatory cytokines and chemokines. In Chapters 2 and 3, we
describe that IL-1-induced mRNA and protein expression of the plasminogen activator
system leads to increased invasion of glioblastoma U373 cells, and that IL-1 stimulation of
primary human astrocytes induces the mRNA expression of two T cell chemotactic
chemokines (IP-10 and RANTES), respectively. More importantly, since IL-1 has been
shown to increase the expression of SphK1 and elevated levels of SphK1 indicate a poor
prognosis for survival for glioblastoma patients , we investigated the role of S1P in the
regulation of the plasminogen activator system and glioblastoma invasion (Chapter 2).
Interestingly, as described in detail in Chapter 3, S1P also abolishes IL-1-induced mRNA
expression of IP-10 and RANTES, which are both essential chemokines for the progression
of MS. Therefore, S1P may be a focal therapeutic agent for the treatment of MS, as it may
reduce the attraction of T cells to MS lesions.

CHAPTER 2
SPHINGOSINE -1-PHOSPHATE AND INTERLEUKIN-1
INDEPENDENTLY REGULATE THE PLASMINOGEN ACTIVATOR
SYSTEM IN GLIOBLASTOMA; IMPLICATIONS FOR
INVASIVENESS
2.1 ABSTRACT
Glioblastoma multiforme is an invasive primary brain tumor, which evades the
current standard treatments. The invasion of glioblastoma cells into healthy brain tissue
partly depends on the proteolytic and non-proteolytic activities of the plasminogen activator
system proteins, including the urokinase-type (uPA) plasminogen activator, plasminogen
activator inhibitor 1 (PAI-1), and a receptor for uPA (uPAR). Here we demonstrate that
sphingosine-1-phosphate (S1P), and the inflammatory mediator IL-1, increase the mRNA
and protein expression of PAI-1 and uPAR and enhance the invasion of U373 glioblastoma
cells. Although IL-1 enhanced the mRNA expression of sphingosine kinase 1 (SphK1), the
enzyme that produces S1P, downregulation of SphK1 had no effect on the IL-1-induced
uPAR or PAI-1 mRNA expression, suggesting that these actions of IL-1 are independent of
S1P production. Indeed, the S1P-induced mRNA expression of uPAR and PAI-1 was
blocked by the S1P2 receptor antagonist JTE013, and by the downregulation of S1P2 using
20
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siRNA. Accordingly, the inhibition of MEK1/2 and Rho-kinase, two downstream signaling
cascades activated by S1P2, blocked the activation of PAI-1 and uPAR mRNA expression by
S1P. More importantly, the attachment of glioblastoma cells was inhibited by the addition of
exogenous PAI-1 or siRNA to uPAR, while the invasion of glioblastoma cells induced by
S1P or IL-1 correlated with their ability to enhance the expression of PAI-1 and uPAR.
Collectively, these results indicate that S1P and IL-1 activate distinct pathways leading to the
mRNA and protein expression of PAI-1 and uPAR, which are important for glioblastoma
invasiveness.
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2.2 INTRODUCTION
Glioblastoma multiforme (GBM) is one of the most common and most malignant
tumors of the central nervous system . Due to the invasive phenotype and diffuse penetration
of GBM into normal regions of the brain, standard treatments such as surgery and
radiotherapy are ineffective . It is for these reasons that patients diagnosed with GBM
survive only an average of 10 to 12 months . The invasion of glioblastoma cells requires the
degradation of the extracellular matrix (ECM), which depends on the activation/inhibition of
proteinases and their inhibitors, respectively. These processes include two main proteolytic
systems: the plasminogen activator system (PAS), which controls the activation of the
proteinase plasmin from inactive plasminogen, and the matrix metalloproteinases and their
inhibitors .
In the brain, microglia produce inactive plasminogen, while astrocytes and glioma
cells produce and secrete the components of the PAS. The PAS includes the plasminogen
activators [urokinase-type (uPA), and the tissue-type (tPA)], their inhibitors [plasminogen
activator inhibitors (PAI-1, -2, and -3) and protease nexin 1], and a receptor for uPA
[urokinase plasminogen activator receptor (uPAR)] . The binding of uPA to uPAR leads to
the localization of proteolytic activity to the cell surface, the enhancement of plasmin
production, and the activation of several signaling pathways via uPAR . Significantly, the
expression of both uPA and uPAR has been correlated with the invasiveness and migration
of several cancer cell lines . Moreover, the knockdown of uPAR expression in gliomas,
using RNAi, leads to a significant decrease in cell invasion in both Matrigel and spheroid
invasion assays . Furthermore, transfecting glioblastoma cells with antisense uPA disrupted
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actin cytoskeleton formation, reduced the amount of cell-bound uPA, and decreased cell
migration . Surprisingly, high levels of PAI-1, which inhibit uPA, have been associated with
highly invasive glioblastomas . Similarly, breast cancer patients with high levels of PAI-1
have a poor prognosis for survival . Together, these observations support the recent findings
that PAI-1 binds to the uPA/uPAR/integrin complex, which promotes the internalization of
this complex, and subsequent cell detachment and metastasis .
The expression of the components of the PAS is regulated by growth factors and
cytokines, such as epidermal growth factor (EGF) and interleukin-1 (IL-1), respectively .
Importantly, increased glioblastoma invasiveness and decreased patient survival correlates
with PAI-1 and EGFR overexpression in tumors . Moreover, inhibition of EGFR tyrosine
kinase suppresses the invasion of glioblastoma cells, and decreases uPAR protein levels .
Recently, we have described a novel signaling pathway of EGF-mediated up-regulation of
PAI-1 expression in glioblastoma cells, which requires the sequential activation of c-Src,
PKCδ, and sphingosine kinase 1 (SphK1; ref in ). SphK1 produces the potent lipid mediator
S1P by phosphorylating sphingosine and its expression correlates with the poor survival of
patients with GBM . S1P has been shown to be mitogenic for several glioma cell lines, and
to enhance their motility and invasiveness . S1P acts through five G protein-coupled
receptors (S1P1-S1P5) to activate multiple signaling pathways; however, it may also have
intracellular actions through mechanisms that are not understood.
IL-1 is a pro-inflammatory cytokine released by inflammatory cells in the brain due
to inflammation caused by an injury or a growing tumor. In addition, glioblastomas have
recently been shown to secrete substantial amounts of IL-1 , which incites the secretion of
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other cytokines, such as IL-6 and IL-8, as well as promotes glioblastoma proliferation . IL-1
has also been shown to stimulate the expression of several MMPs, tPA, uPA , yet nothing is
known of its role in invasion of glioblastomas. Because IL-1 has been shown to activate
SphK1 in other cell types , we investigated the effects of IL-1 and S1P on regulation of the
components of the PAS system and invasion in glioblastoma cells. We show that S1P
requires S1P2 to activate PAI-1 and uPAR mRNA expression, and although IL-1 markedly
upregulates the mRNA expression of SphK1, it acts independently of S1P. Moreover, S1P
and IL-1 cooperatively increase the invasion of U373 glioblastoma cells, as well as primary
non-established GBM6 glioblastoma cells. Our data highlights the role of S1P and IL-1 in
the regulation of PAI-1 and uPAR mRNA and protein expression, which are critical for
glioblastoma invasiveness.
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2.3 MATERIALS AND METHODS
2.3.1 Cell Culture. Human glioblastoma U373-MG cells were obtained from the American
Type Culture Collection (Herndon, VA), while primary human non-established glioblastoma
GBM6 and GBM12 cells were kindly provided by Dr. C. David James (University of
California, San Francisco, CA). The U373-TAM67 cells expressing the dominant-negative
c-jun(TAM67) were described previously . Cells were cultured in Dulbecco's modified
Eagle's medium supplemented with 10% fetal calf serum, antibiotics, sodium pyruvate, and
non-essential amino acids.

2.3.2 Cytokines and cell stimulation. Cells were stimulated with 10 ng/ml IL-1 (a gift from
Immunex Corp., Seattle, WA) or the indicated amounts of S1P, as described previously .
For the inhibitor studies, cells were pretreated with 1 µM SP600125, 10 µM SB202190
(Sigma-Aldrich, St. Louis, MO), 1 µM JTE-013 (Tocris, Ellisville, MO), 0.3 µM VPC23019
(Avanti Polar Lipids, Alabaster, Al), 5 µM Y27632, 5 µM Gö6983 (EMD Biosciences, Inc.,
San Diego, CA), 10 µM LY294002, or 1 µM U0126 1hr prior to stimulation (Cell Signaling
Technology, Inc., Beverly, MA).

2.3.3 Northern blot analysis. Total RNA was prepared by phenol extraction exactly as
described previously . Five-microgram samples of RNA were subjected to formaldehyde gel
electrophoresis using standard procedures and transferred onto Hybond-XL membranes (GE
Healthcare Bio-Sciences Corp.) according to the manufacturer’s instructions. The filters
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were prehybridized at 65°C for 3 h in 0.5 M sodium phosphate buffer pH 7.2, 7% SDS, and
1 mM EDTA. Then the filters were hybridized in the same solution with cDNA fragments of
PAI-1, uPAR, and uPA labeled by random priming . After the hybridization, nonspecifically
bound radioactivity was removed by four washes in 40 mM phosphate buffer, 1% SDS, and
1 mM EDTA at 65°C for 20 min each.

2.3.4 Quantitative PCR (qPCR) uPAR, uPA, PAI-1, SphK1, and GAPDH mRNA levels
were measured using TaqMan technology (Applied Biosystems, Foster City, CA) according
to the supplier’s instructions. Briefly, one µg of total RNA was reverse-transcribed using the
high capacity cDNA archive kit. Subsequently, the cDNA was diluted 10-fold (uPAR, uPA,
PAI-1, and SphK1) or 100-fold (GAPDH). For real-time PCR, pre-mixed primer-probe sets
and TaqMan Universal PCR Master Mix were purchased from Applied Biosystems, and the
cDNA was amplified using an ABI 7900HT cycler.
2.3.5 Western blotting. Cells were lysed in 10 mM Tris pH 7.4, 150 mM sodium chloride, 1
mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 mM PMSF,
and protease inhibitor cocktail (Roche, Mannheim, Germany). The protein amounts were
quantified using the BCA assay. Subsequently, equal amounts of the proteins were resolved
using SDS-PAGE, and electroblotted onto nitrocellulose membranes (Schleicher & Schuell,
Keene, NH). Polyclonal anti-ERK and anti-IκBα antisera were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA), while anti-phospho-ERK and anti-phospho-JNK were
purchased from Cell Signaling Technology, Inc. (Beverly, MA).

Antigen-antibody
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complexes were visualized by enhanced chemiluminescence according to the manufacturer’s
instructions (Pierce, Rockford, IL).

2.3.6 Downregulation with siRNA. Cells were equally plated at approximately 70%
confluency. S1P2, PAI-1, and uPAR expression was downregulated using SmartPool siRNA
purchased from Dharmacon, Inc. (Lafayette, CO). The siRNA (10µM) was transfected into
the cells using Dharmafect 1 (Dharmacon) for 48hrs.

2.3.7 Attachment assay. Cells were scraped off the dishes in PBS, and dissociated by
pipetting. The cells were pelleted by centrifugation, counted, and resuspended in FBS-free
DMEM at 100,000 cells/200 µl. Subsequently, the cells were incubated with 1 µM PAI-1
(EMD Biosciences, Inc., San Diego, CA), or 1 µM BSA for 10 minutes at 37°C, and plated
onto vitronectin-coated dishes. The cells were allowed to adhere for 10 minutes, the medium
containing the non-attached cells was removed, centrifuged, and the cells were counted in
the presence of trypan blue using a hemocytometer. The attachment assay that was
performed after transfection with PAI-1 or uPAR siRNA, was performed as described above
with minor differences (50,000 cells/200 µl and the cells were allowed to adhere for 5
minutes).

2.3.8 Invasion assay. The cells were stimulated with S1P (5 µM) and/or IL-1 (10 ng/ml) for
18 hours. The invasion of the cells was subsequently measured in a modified Boyden
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chamber, using polycarbonate filters (25 by 80 mm, 12 μm pore size) coated with Matrigel
(BD, Franklin Lakes, NJ; ref. ). Both IL-1 (10ng/ml) and S1P (100 nM) were added to both
the upper and lower chamber, while the cells were added to the upper chamber at 5×10 4
cells/well. After 7 h, non-migratory cells on the upper membrane surface were mechanically
removed, and the cells that traversed and spread on the lower surface of the filter were fixed
with methanol and stained with Diff-Quik (Fisher Scientific, Pittsburgh, PA). The invading
cells were counted with an inverted microscope and a 10× objective . Each data point is the
average number of cells in five random fields, and is the mean ± standard deviation (SD) of
three individual wells.
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2.4 RESULTS
2.4.1 S1P and IL-1 regulate the expression of the PAS in glioblastoma cells.
Previous studies have suggested that S1P might regulate invasion of glioblastoma cells ,
yet the mechanism involved remained elusive. To this end, U373 glioblastoma cells were
stimulated with both S1P and IL-1, since glioblastomas have recently been shown to secret
substantial amounts of this neuroinflammatory cytokine , which also activates PAI-1 . Both
S1P and IL-1 efficiently stimulated the mRNA (both transcripts generated by the alternative
cleavage and polyadenylation; ref. ) and protein expression of PAI-1 and uPAR, while the
mRNA expression of uPA was unaffected (Fig. 2.1A, B, and C). The effect of exogenous
S1P on PAI-1 and uPAR mRNA expression was time- and dose-dependent, with activation
observed as early as one hour after stimulation (Fig. 2.1D). Maximum activation of PAI-1
and uPAR mRNA expression was observed at 5 µM S1P, but the effect was significant at a
concentration as low as 10 nM. These results indicate that S1P affects the mRNA expression
of the PAS components in glioblastoma cells, and its effects are further enhanced by IL-1.
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Figure 2.1 S1P and IL-1 up-regulate the expression of uPAR and PAI-1 in glioblastoma
cells. U373 cells were treated with 10 ng/ml IL-1 or 5 µM S1P for 18 hours (A, B, and C),
stimulated with 5 µM S1P for the indicated times (D, left panels), or stimulated with the
indicated amounts of S1P or 10 ng/ml IL-1 for 18 hours (D, right panel). (C) Media were
collected and cell lysates prepared and analyzed by Western blotting as discussed in
Materials and Methods. RNA was isolated and subjected to analysis either by Northern
blotting or qPCR using TaqMan technology. The lower panels in A and D show 28S RNA
stained with ethidium bromide on the membrane as a loading control. The qPCR data were
normalized to GAPDH mRNA, and expressed as a ratio to mRNA levels in untreated cells.
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2.4.2 S1P activates PAI-1 and uPAR mRNA expression via multiple signaling
pathways.
The additive activation of both PAI-1 and uPAR mRNA expression by the combination
of S1P and IL-1 (Fig. 2.1B), suggests that they may regulate the mRNA expression of these
genes by distinct pathways. Both S1P and IL-1 have been shown to activate various
signaling pathways in many cell types, leading to the reprogramming of gene expression
profiles .

In glioblastoma cells, both S1P and IL-1 induced rapid phosphorylation of

ERK1/2; however, the phosphorylation of JNK and the efficient degradation of IκBα, which
is important for the activation of NF-κB, were restricted to IL-1 (Fig. 2.2A). We employed
several pharmacological inhibitors in order to identify the signaling pathway(s) regulating
PAI-1 and uPAR mRNA expression in response to S1P in U373 cells. The inhibition of
PI3K and p38 (using LY294002 and SB202190, respectively) diminished the intrinsic
mRNA expression of PAI-1, but did not affect the relative fold activation by S1P (Fig.
2.2B). In contrast, the inhibition of MEK1/2 and Rho-kinase (using U0126 and Y27632,
respectively) blocked PAI-1 and uPAR upregulation by S1P (Fig. 2.2C). In addition, the
S1P-mediated uPAR activation was also inhibited by LY294002. These results suggest that
diverse signaling molecules, including MEK/ERK and Rho-kinase, regulate the mRNA
expression of PAI-1 and uPAR in response to S1P. Since both MEK/ERK and Rho-kinase
can activate AP-1 and both PAI-1 and uPAR expression are regulated by AP-1 in response to
various stimuli , we tested whether this potent transcription factor may be implicated in the
regulation of PAI-1 and uPAR mRNA expression in response to S1P and IL-1. We utilized
U373-TAM67 cells inducibly
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Figure 2.2 Signaling pathways involved in S1P-stimulateed mRNA expression of PAI-1
and uPAR. (A) U373 cells were stimulated with 10 ng/ml IL-1 or 5 µM S1P for the
indicated times. The cell lysates were prepared, and analyzed by Western blotting with antiphospho-ERK, anti-phospho-JNK, anti-IκBα, anti-ERK. Blots were stripped and re-probed
with anti-tubulin antibodies to insure equal loading and transfer. (B, C) U373 cells were
pretreated with 1 µM U0126, 10 µM LY294002, 1 µM SP600125, 10 µM SB202190, 5 µM
Go6983, or 5 µM Y27632 for 1 hour, and subsequently stimulated with 5 µM S1P for 18
hours. RNA was isolated, and the mRNA expression of PAI-1 (B) and uPAR (C) was
analyzed by qPCR. The data were normalized to GAPDH mRNA, and expressed as a ratio
to mRNA levels in untreated cells. Asterisks indicate statistically significant inhibition.
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overexpressing dominant-negative c-jun(TAM67), which quenches the expression of AP-1dependent genes . The intrinsic mRNA expression of PAI-1, its fold activation by both S1P
and IL-1, and the marked increase by their combination were diminished, thus indicating that
AP-1 is involved in the regulation of PAI-1 mRNA expression (Fig. 2.3). In contrast, the
mRNA expression of uPAR was not affected by c-jun(TAM67) overexpression (Fig. 2.3).
These results argue that while genes encoding PAI-1 and uPAR are regulated by signals
initiated by S1P and IL-1, the precise mechanisms of their regulation are distinct.

2.4.3 IL-1-activated PAI-1 and uPAR mRNA expression is SphK1-independent.
Since IL-1 rapidly activates and upregulates the expression of SphK1 in several other
cell types , we examined the effect of IL-1 on SphK1 mRNA expression in glioblastoma
cells. The mRNA expression of SphK1 was significantly upregulated by IL-1 in U373 cells
(Fig. 2.4A). Thus, the IL-1-induced PAI-1 and uPAR mRNA expression could potentially
be due to elevated levels of S1P produced in response to IL-1. Because in many other cell
types, S1P produced by agonist-stimulated SphK1 can activate cell surface S1P receptors in
an autocrine/paracrine manner , this possibility was examined by downregulating the
expression of SphK1 with specific siRNA in U373 cells. However, IL-1-induced mRNA
expression of PAI-1 and uPAR was not affected by the downregulation of SphK1 (Fig. 2.4B
and C), thus indicating that this activation is SphK1-independent.
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Figure 2.3 AP-1 is necessary for PAI-1, but not uPAR mRNA expression U373-TAM67
cells were preincubated with 1 µg/ml of tetracycline for 24 hours, and then stimulated with
10 ng/ml IL-1 or 5 µM S1P for 18 hours, RNA was isolated and analyzed as in (2.2 B, C).
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Figure 2.4 Upregulation of PAI-1 and uPAR mRNA by IL-1 is independent of SphK1.
U373 cells were transfected with control or SphK1 siRNA for 48 hours, and then stimulated
with or without 10 ng/ml IL-1 for 18 hours, as indicated. RNA was isolated, and the mRNA
expression of SphK1 (A), PAI-1 (B) and uPAR (C) was analyzed by qPCR. The data were
normalized to GAPDH mRNA, and expressed as a ratio to mRNA levels in untreated cells.
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2.4.4 S1P activates PAI-1 and uPAR mRNA expression via the S1P2 receptor.
Given that most of the effects of S1P are mediated by binding to specific cell surface
receptors , of which S1P1-3 are expressed by U373 cells , it was of interest to identify the S1P
receptor(s) mediating the activation of PAI-1 and uPAR mRNA expression. To this end, we
utilized both pharmacological and molecular approaches. First, antagonists VPC23019 and
JTE-013 were used to block the S1P1 and S1P2 receptors, respectively. Inhibition of S1P2
abrogated the activation of PAI-1 and uPAR mRNA expression by S1P, while the inhibition
of S1P1 was ineffective (Fig. 2.5A and B). Moreover, neither the inhibition of S1P1 nor S1P2
had any effect on the IL-1 activated mRNA expression of PAI-1 and uPAR (Fig. 2.5C and
D), thus suggesting that the activation by IL-1 does not require these two receptors. Second,
the mRNA expression of S1P2 was down-regulated by more than 80% by S1P2 specific
siRNA (Fig. 2.6A).

In agreement with the pharmacological inhibition of S1P2, the

downregulation of S1P2 expression abolished the activation of PAI-1 and uPAR mRNA
expression by S1P, without affecting the response to IL-1 (Fig. 2.6B and C). These results
indicate that S1P specifically activates PAI-1 and uPAR mRNA expression via the S1P2
receptor.
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Figure 2.5 Inhibition of S1P2 blocks the induction of PAI-1 and uPAR mRNA by S1P.
U373 cells were pretreated with 0.3 µM VPC23019 or 1 µM JTE-013 for 30 min., and
subsequently stimulated with 5 µM S1P (A, B) or 10 ng/ml IL-1 (C, D) for 18 hours. RNA
was isolated, and the mRNA expression of PAI-1 (A, C) and uPAR (B, D) was analyzed by
qPCR. The data were normalized to GAPDH mRNA, and expressed as a ratio to mRNA
levels in untreated cells.
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Figure 2.6 Knock-down of S1P2 expression abrogates S1P-induced upregulation of
PAI-1 and uPAR mRNA. U373 cells were transfected with control or S1P2 siRNA for 48
hours. Then the cells were stimulated without or with 10 ng/ml IL-1 or 5 µM S1P as
indicated, for 18 hours. RNA was isolated, and the expression of S1P2 mRNA (A), PAI-1
(B) and uPAR (C) mRNA was analyzed by qPCR. The data were normalized to GAPDH
mRNA, and expressed as a ratio to mRNA levels in untreated cells. Asterisks indicate
statistically significant inhibition.
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2.4.5 PAI-1 and uPAR are critical for the IL-1- and S1P-induced invasion of
glioblastoma cells.
Subsequently, we examined the roles of PAI-1, uPAR, S1P, and IL-1 in the invasion of
glioblastoma cells. The invasion of U373 cells into Matrigel was significantly increased in
response to both S1P and IL-1 (Fig. 2.7B). More importantly, the S1P- and IL-1-induced
invasion was abrogated in U373 cells when the expression of either PAI-1 or uPAR was
downregulated (Fig. 2.7B). Thus, both IL-1 and S1P increase the invasion of glioblastoma
cells via PAI-1 and uPAR expression. Since PAI-1 binds to, and induces the internalization
of the PAI-1/uPA/uPAR/integrin complex, which cause cell detachment in breast cancer
cells , we evaluated whether PAI-1 can interfere with the attachment of U373 cells. Indeed, 1
µM PAI-1 inhibited the attachment of U373 cells to vitronectin-coated dishes (Fig. 2.8).
These results suggest that PAI-1 may also regulate detachment of glioblastoma cells.
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Figure 2.7 PAI-1 and uPAR are indispensable for S1P- and IL-1-enhanced invasion of
U373 cells. (A,B) U373 cells were transfected with control, uPAR, or PAI-1 siRNA for 48
hours, as indicated. (A) RNA was isolated, and the expression of uPAR and PAI-1 mRNA
was analyzed by qPCR. The data were normalized to GAPDH mRNA, and expressed as a
ratio to mRNA levels in untreated cells. (B) Duplicate cultures were stimulated with or
without 10 ng/ml IL-1 or 100 nM S1P for 12 hours, and allowed to migrate through
polycarbonate filters coated with Matrigel for 7 hours. The invasion was measured as
described in the Materials and Methods. The results are means ± SD from three independent
experiments.
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Figure 2.8 PAI-1 increases detachment of U373 cells. (A) U373 cells were incubated with
1 µM PAI-1 or 1 µM BSA for 10 minutes, plated onto vitronectin-coated dishes, and
allowed to adhere for 20 minutes. Subsequently, the medium containing the non-attached
cells was removed, and the number of cells present in the medium was counted using a
hemocytometer. (B) U373 cells were transfected with control, uPAR, or PAI-1 siRNA for 48
hours, as indicated. The cells were plated, allowed to adhere, removed, and counted exactly
as performed in (A). The results are means ± SD from two independent experiments done in
triplicate.
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2.4.6 PAI-1 and uPAR mRNA expression is regulated by S1P and IL-1 in primary nonestablished glioblastomas.
Glioblastoma cell lines, commonly used in in vitro studies, are not invasive in in vivo
animal models . Therefore, we examined the effects of S1P and IL-1 on primary nonestablished glioblastoma cells (GBM6 and GBM12), which were shown to produce invasive,
diffuse tumors in scid mice . mRNA expression of PAI-1 and uPAR was increased by S1P
and IL-1 in GBM6 cells (Fig. 2.9A, B). However, whereas S1P increased PAI-1 in GBM12
cells, IL-1 increased uPAR without affecting PAI-1 (Fig. 2.9A, B). In contrast to U373 cells,
the mRNA expression of uPA was also upregulated by S1P and IL-1 in both of these nonestablished GBM cells (Fig. 2.9C). Moreover, the invasion of GBM6 cells into Matrigel was
significantly increased in response to both S1P and IL-1 (Fig. 2.9D), while GBM 12 cells
were not invasive (Fig. 2.9D), likely due to the extremely low levels of uPAR in these cells.
Thus, both S1P and IL-1 play important roles in regulating the expression of the PAS
components, and the invasion of primary glioblastoma cells.
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Figure 2.9 IL-1 and S1P upregulate the mRNA expression of PAI-1 and uPAR in
primary non-established GBMs and stimulate their invasion. Primary non-established
glioblastoma GBM6 and GBM12 cells were stimulated without or with 10 ng/ml IL-1 or 5
µM S1P for 18 hours. RNA was isolated, and the expression of PAI-1 (A), uPAR (B), and
uPA (C) was analyzed by qPCR. The data were normalized to GAPDH mRNA, and
expressed as a ratio to mRNA levels in untreated cells. (D) GBM6 and GBM12 cells
(50,000 cells/well) were stimulated without or with 10 ng/ml IL-1 or 100 nM S1P, and
allowed to migrate through polycarbonate filters coated with Matrigel for 7 hours. The
invasion was measured as described in the Materials and Methods. The results are means ±
SD from three independent experiments.
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2.5 DISCUSSION
The invasive phenotype of glioblastoma cells is the major obstacle in the successful
treatment of patients diagnosed with GBM. While the precise mechanisms leading to the
diffuse penetration of individual cells into normal regions of the brain are not understood, it
is known that their invasion is regulated by growth factors, cytokines, and other signaling
molecules, including bioactive lipids. Among cytokines and growth factors, IL-1 and EGF
have attracted most of the attention. EGF is produced in the brain and readily crosses the
blood-brain barrier , while its receptor (EGFR) is frequently amplified , overexpressed , or
mutated in glioblastomas. Furthermore, the amplification and overexpression of EGFR is
associated with high-grade progression , and patients expressing high levels of both EGFR
and PAI-1 have a shorter prognosis for survival . Similarly to EGF, IL-1 is readily found in
the brain, and can be produced by activated microglia and astrocytes surrounding the
necrotic center of a glioblastoma tumor.

In addition, significant amounts of IL-1 are

produced by glioblastomas . IL-1, as a potent neuroinflammatory cytokine, activates the
expression of many genes in astrocytes and glioblastoma cells, including the genes encoding
PAI-1 and SphK1. Similarly, we have recently shown that EGF stimulates PAI-1 mRNA
expression in glioblastomas via the activation of SphK1 , the enzyme that produces S1P.
In this paper, we show that exogenous S1P activates PAI-1 and uPAR mRNA expression
in both U373 cells (Fig. 2.1), as well as in primary invasive GBMs (Fig. 2.9). In addition,
S1P enhances uPA mRNA expression in primary GBMs. However, the precise cellular
localizations of PAI-1, uPA, and uPAR are likely critical, since the attachment at the leading
edge of a migrating cell, and the concurrent detachment at its trailing edge is imperative for
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efficient migration and invasion. More importantly, the enhanced expression of the PAS
components may provide both the attachment, as well as the detachment depending on the
ratio of PAI-1, uPA, and uPAR at specific locations on the cell’s membrane. Indeed, uPAR
is mainly found at focal adhesion areas, rafts, and caveolae at the leading edge of migrating
cells . uPAR is bound to catalytically active uPA, leading to the degradation of the ECM,
and providing attachment via the uPA/uPAR/integrins complex. In contrast, the enhanced
expression of PAI-1 on the trailing edge of migrating cells may induce the internalization of
the uPA/uPAR/integrin complex, and result in cell detachment.
Our data indicate that the S1P-induced mRNA expression of PAI-1 and uPAR is
mediated by S1P2, as shown using pharmacological inhibitors and specific siRNA. S1P2
inhibits glioma cell migration through Rho activation and the Rho-kinase signaling
pathway , which is probably mediated by PTEN activation . However, a recent study
demonstrates that S1P2 inhibits glioma cell migration through Rho signaling pathways
independent of PTEN . In agreement with our results, S1P2 was recently reported to enhance,
rather than suppress, invasion most likely by increasing cell adhesion . In addition, we show
that S1P2 may also control the generation of plasmin, which is critical for the degradation of
the ECM, by regulating the expression of PAI-1 and uPAR.

The S1P2-mediated

upregulation of PAI-1 and uPAR required functional Rho-kinase and MEK1. The increased
mRNA expression of uPAR induced by both S1P and IL-1 was AP-1-independent as shown
in U373-TAM67 cells. In contrast, the intrinsic mRNA expression of PAI-1, and the fold
stimulation by both S1P and IL-1 was decreased in U373-TAM67 cells, suggesting that this
gene is regulated at least in part by AP-1.
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Moreover, we showed that IL-1 acts independently of S1P to stimulate PAI-1 and
uPAR mRNA expression in U373 cells, as well as in primary GBMs. This may be relevant
in vivo, since IL-1 is secreted by the majority of GBMs . IL-1 can also regulate the levels of
S1P in vivo, since it strongly upregulates the expression of SphK1 (Fig. 2.4A). However, the
IL-1-mediated increase of PAI-1 and uPAR mRNA expression is independent of SphK1, and
thus independent of S1P formation. These data are further supported by the observation that
the knockdown of S1P2 expression does not affect the IL-1-induced mRNA expression of
PAI-1 and uPAR. An additional role for IL-1 may lie in its ability to stimulate the mRNA
expression of SphK1, thus maintaining a sustained pool of S1P, which is known to be critical
for glioblastoma cell growth and survival . More import, we demonstrate that the in vitro
invasion of both U373 cells, and primary GBM6 cells was increased in response to both S1P
and IL-1. Furthermore, the down-regulation of both PAI-1 and uPAR expression abrogated
S1P- and IL-1-induced invasion. Therefore, we propose that IL-1 and S1P independently
stimulate the invasion of glioblastoma cells via upregulating PAI-1 and uPAR expression.
These observations have important implications for development of future therapeutic agents
to limit the invasion of GBM cells into surrounding healthy tissue, thus allowing for the
effective removal of the tumor.

CHAPTER 3
NOVEL SPHINGOSINE -1-PHOSPHATE MEDIATED SUPPRESSION
OF INTERLEUKIN-1-INDUCED CHEMOKINE EXPRESSION IN
PRIMARY HUMAN ASTROCYTES
3.1 ABSTRACT
Multiple sclerosis (MS), an inflammatory disease of the central nervous system, is
hallmarked by chronic inflammation, demyelination, and brain atrophy. The pathology of
this disease is mostly due to autoreactive T cells that invade the blood-brain barrier, and
become activated. In the brain, T cells are attracted to sites of inflammation by chemokines
released by activated microglia and astrocytes. Interestingly, two potent T cell chemokines,
interferon gamma inducible protein-10 (IP-10) and regulated on activation normal T-cellexpressed and secreted (RANTES), are up-regulated in MS lesions. Here we show for the
first time that in primary human astrocytes, sphingosine -1-phosphate (S1P), the bio-active
sphingolipid, can significantly repress IP-10 and RANTES mRNA expression induced by the
major proinflammatory cytokine of the brain, interleukin-1 (IL-1). IL-1 activates IP-10 and
RANTES mRNA expression by inducing interferon beta (IFNβ) mRNA expression, and
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subsequently the activation/phosphorylation of STAT1 and STAT2, which are known to be
important for IP-10 and RANTES promoter activity. More importantly, S1P inhibits IFNβ
production, STAT1 and STAT2 activation, and IP-10 and RANTES mRNA expression, via a
novel mechanism involving the hyper-phosphorylation of TAK1, which is a key component
of the IL-1 signaling pathway. In addition, the S1P repression of IP-10 and RANTES is
receptor-mediated, and depends on the Gi protein, as it is pertussis toxin sensitive and can be
blocked by S1PR antagonists. These significant results could have implications for future
MS therapies utilizing S1P as a natural compound to reduce self-destructive inflammation.
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3.2 INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS that affects
over one million people worldwide . It affects women twice as often as men, and it typically
occurs in young adults. The disease is characterized by demyelination, axonal loss, and brain
atrophy . Demyelination produces plaques, which are areas of white matter where in the
inflammatory response has removed the myelin from neurons, and cells such as actrocytes
and microglia have caused scarring. Hence, the major pathology of MS is due to the
inflammatory response, specifically autoreactive T cells. In fact, in the animal model of MS,
experimental autoimmune encephalomyelitis (EAE), the basic requirement for stimulating
CNS inflammation and MS is activation of myelin reactive T cells in the peripheral immune
system .
In the brain, T cells and other immune cells are directed to sites of inflammation by
chemotactic cytokines, called chemokines, which are released by activated microglia and
astrocytes. Interestingly, two T cell chemotatic chemokines, interferon γ inducible protein-10
(IP-10) and regulated on activation normal T cell expressed and secreted (RANTES), have
been found to be up-regulated in lesions of MS patients (85,86,91,92). Moreover, antiCXCL10 (IP-10) mAbs reduce disease occurrence, severity, and invasion of mononuclear
cells . In addition, a RANTES variant (termed
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AANA47-RANTES), which lacks

glycosaminoglycan (GAG) binding properties , impedes disease onset and diminishes
disease score in the EAE model . Thus, treatments that target these chemokines may be
efficacious as future therapies for MS patients.
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Interestingly, increased levels of interleukin-1 (IL-1), the major pro-inflammatory
cytokine in the brain, have also been found in MS lesions [66, 68]. IL-1 is released from
activated microglia and astrocytes during inflammation, and has been shown to increase the
expression of a variety of cytokines and chemokines, including IL-8, IL-6, TNFα, MCP-1,
MIP-1α, MIP-1β, IP-10, and RANTES . More interestingly, in primary human astrocytes,
IL-1 also increases the expression of sphingosine kinase 1 (SphK1), which is the enzyme
responsible for producing the bioactive sphingolipid, sphingosine-1-phosphate (S1P) .
S1P has been implicated in cell proliferation, survival, angiogenesis, migration, and
differentiation in an assortment of cell types . S1P can act both intracellularly as a second
messenger, and extracellularly, in an autocrine/paracrine manner, by binding to its five
transmembrane G-protein coupled receptors (S1P1-5) ; however, only S1P1-3 and S1P5 are
expressed in the brain . The individual S1P receptors can couple to a distinct group of G
proteins, with varying affinities for different affecter molecules, which can lead to the
activation of mitogen-actvated protein kinase (MAPK/ERK), phospholipase C (PLC), PI3K,
Rac, Rho, and JNK (Rev. in ). Notably, all of the S1P receptors are capable of coupling to
the Gi protein; while only S1P2 and S1P3 can couple to Gq, and only S1P2, S1P3, and S1P5
couple to G12/13 . Furthermore, S1P receptors are significantly increased in the borders of MS
lesions .
Here we demonstrate for the first time, that IL-1-induced IP-10 and RANTES mRNA
expression is abolished by S1P in primary human astrocytes. The S1P-directed suppression
of IL-1-induced IP-10 and RANTES mRNA expression is Gi mediated, and involves a key
component of IL-1 signaling, TAK1. Furthermore, S1P suppression of IP-10 and RANTES
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mRNA expression also occurs in other cell types, including MEFs (mouse embryonic
fibroblasts) and HeLa cells. Moreover, S1P also suppresses TNFα-induced mRNA
expression of IP-10 and RANTES. Thus, S1P is capable of suppressing cytokine induced
mRNA expression of T cell chemokines in primary human astrocytes, and therefore, a
natural sphingolipid (S1P) may be an important therapeutic agent for inhibiting the T cell
response in MS patients in the future.
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3.3 MATERIALS AND METHODS
3.3.1 Cell culture. Human glioblastoma U373-MG and HeLa epitheloid cervix carcinoma
cells were obtained from the American Type Culture Collection (Herndon, VA). Mouse
embryonic fibroblasts were purchased from Millipore Corporation, Phillipsburg, NJ, while
TAK1 KO MEFs were kindly provided by Dr. Xiaoxia Li (Cleveland Clinic Foundation,
Cleveland, OH). Cells were cultured in Dulbecco's modified Eagle's medium supplemented
with 10% fetal calf serum, antibiotics, sodium pyruvate, and non-essential amino acids. Prior
to stimulation, cells were cultured overnight in Dulbecco’s modified Eagle’s medium
supplemented with 1% fetal calf serum, antibiotics, sodium pyruvate, and non-essential
amino acids.

3.3.2. Primary human astrocytes culture. Human cortical astrocyte cultures were
established using dissociated human cerebral tissue, as previously described . Cortical tissue
was provided by Advanced Bioscience Resources (Alameda, CA), and the protocol for
obtaining postmortem fetal neural tissue complied with the federal guidelines for fetal
research and with the Uniformed Anatomical Gift Act. Cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum, penicillin and
streptomycin, sodium pyruvate, and non-essential amino acids. Prior to stimulation, cells
were cultured overnight in Dulbecco’s modified Eagle’s medium supplemented with 1%
fetal calf serum, antibiotics, sodium pyruvate, and non-essential amino acids.
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3.3.3 Cytokines and cell stimulation. Cells were stimulated with 10 ng/ml or the indicated
amounts of IL-1α (a gift from Immunex Corp., Seattle, WA), 10 ng/ml IL-1β (R&D,
Systems, Inc., Minneapolis, MN), 10 ng/ml of human cell expressed IL-1β (Humanzyme,
Chicago, IL), 100 pg/ml LPS (Sigma-Aldrich, St. Louis, MO), 5 ng/ml TNFα (R&D,
Systems, Inc., Minneapolis, MN), 1000 u/ml IFNα and 1000 u/ml IFNβ were a kind gift of
Dr. Darren P. Baker (Biogen Indec Inc), 1000 u/ml IFNγ (R&D, Systems, Inc., Minneapolis,
MN), or the indicated amounts of S1P, as described previously . For the inhibitor studies,
cells were pretreated with 1 µM JTE-013 (Tocris, Ellisville, MO), or 10 µM VPC23019
(Avanti Polar Lipids, Alabaster, AL) 30 min prior to stimulation. Cells were also pretreated
with 5 µM Bay11-7082 inhibitor (Sigma-Aldrich, St. Louis, MO), 15 µM MG132
Proteasome Inhibitor (Santa Cruz, CA), and 20 µg/ml cycloheximide (Sigma-Aldrich, St.
Louis, MO) for 1 hr prior to stimulation; whereas, 600 nM TAK1 inhibitor (AnalytiCon
Discovery, Potsdam, Germany) and 200 ng/ml pertussis toxin (Sigma-Aldrich, St. Louis,
MO) were used for 3 hrs and 24 hrs prior to stimulation, respectively.

3.3.4 RNA preparation and quantitative PCR (qPCR). Cultured cells were lysed by
Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions to prepare
total RNA. IL-8, MIP-1β, IP-10, RANTES, IFNβ, IL-6, mouse IP-10, mouse RANTES,
mouse GAPDH, and GAPDH mRNA levels were measured using TaqMan technology
(Applied Biosystems, Foster City, CA) according to the supplier’s instructions. Briefly, one
µg of total RNA was reverse-transcribed using the high capacity cDNA archive kit.
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Subsequently, the cDNA was diluted 10-fold (IL-8, MIP-1β, IP-10, RANTES, IFNβ, IL-6,
mouse IP-10, and mouse RANTES) or 100-fold (mouse GAPDH and GAPDH). For realtime PCR, pre-mixed primer-probe sets and TaqMan Universal PCR Master Mix were
purchased from Applied Biosystems, and the cDNA was amplified using an ABI 7900HT
cycler.

3.3.5 Reporter constructs and transient transfections. Cells were transiently transfected
in 12 well clusters by FuGENE6 transfection reagent (Roche, Indianapolis, IN) according to
the supplier’s instructions. For the Luciferase reporter assays, four hundred ng of the reporter
Luciferase plasmids NFκB-Luc (Stratagene, USA), pGL-IP-10Luc, pTGL-IP10Luc, pISREIP10Luc, pκB2-MutLuc (all of which were donated by Dr. Richard Ransohoff (Cleveland
Clinic Foundation, Cleveland, OH), as well as 100 ng of the expression plasmid encoding βgalactosidase were used per well in a 12 well cluster.

3.3.6 Western blotting. Cells were lysed in 10 mM Tris pH 7.4, 150 mM sodium chloride,
1 mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 mM PMSF,
and protease inhibitor cocktail (Roche, Mannheim, Germany). The protein amounts were
quantified using the BCA assay. Subsequently, equal amounts of the proteins were resolved
using SDS-PAGE, and electroblotted onto nitrocellulose membranes (Schleicher & Schuell,
Keene, NH). Polyclonal anti-IkBα, anti-phospho-MEKK1, anti-β-tubulin, anti-phospho-cJun, and anti-IRAK1 antisera were purchased from Santa Cruz Biotechnology, Inc. (Santa
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Cruz, CA). The anti-TAK1, anti-phospho-TAK1 (Thr184/187), anti-phospho-TAK1
(Ser412), anti-p38, anti-phospho-p38, anti-phospho-IKKα/β, anti-phospho-MKK4, antiphospho-MKK3/6, anti-phopho-STAT1, anti-phospho-STAT2, anti-phospho-ATF2, antiphospho-p65, and anti-phospho-JNK were purchased from Cell Signaling Technology, Inc.
(Beverly,

MA).

Antigen-antibody

complexes

were

visualized

by

enhanced

chemiluminescence according to the manufacturer’s instructions (Pierce, Rockford, IL).
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3.4 RESULTS
3.4.1 S1P represses IL-1-induced mRNA expression of IP-10 and RANTES in human
primary astrocytes.
Previous studies have shown that IL-1 induces the expression of various chemokines
(IL-8, MIP-1β, IL-6, IP-10, and RANTES) [94,95] in astrocytes, and it also stimulates the
expression and activation of sphingosine kinase-1 (SphK1), and thus the generation of S1P.
Conversely, nothing is known about the regulation of these chemokines by S1P in astrocytes.
To this end, primary human astrocytes were stimulated with both S1P and IL-1. IL-1
significantly enhanced the mRNA expression of IP-10 and RANTES in these cells, while
S1P greatly inhibited the stimulation by IL-1 (Figure 3.1 A and B). It is also important to
note that the kinetics of IP-10 and RANTES stimulation by IL-1 was very different, as IP-10
mRNA expression peaked at 8 hours, while RANTES mRNA expression continued to
increase up to 18 hours. In order to determine the specificity of the S1P chemokine
suppression, we also examined the mRNA expression levels of IL-8, IL-6, and MIP-1β after
S1P and IL-1 stimulation. In contrast to IP-10 and RANTES expression, S1P synergized
with IL-1 to increase the mRNA expression of IL-8, IL-6, and MIP-1β (Figure 3.2 A, B, and
C). These results indicate that S1P specifically represses IP-10 and RANTES mRNA
expression.
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Figure 3.1 S1P inhibits IL-1-induced mRNA expression of IP-10 and RANTES. Primary
human astrocytes were stimulated with 10 ng/ml IL-1, or 5 µM S1P for the indicated times
(A, B). RNA was isolated, and analyzed by qPCR using Taqman technology. qPCR data
were normalized to GAPDH mRNA, and expressed as a ratio to mRNA levels in untreated
cells. The experiment was performed two times, and one is shown.
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Figure 3.2 S1P and IL-1 up-regulate the mRNA expression of the IL-8, IL-6, and
MIP-1β genes. Astrocytes were treated with 10 ng/ml IL-1 and 5 µM S1P for the indicated
times. RNA was isolated, and the expression of IL-6 (A), IL-8 (B), and MIP-1β (C) were
analyzed by qPCR using TaqMan technology. Data were normalized to GAPDH, and
expressed as a ratio to mRNA levels in untreated cells. The experiment was performed two
times, and a representative is shown.

69

70
3.4.2 S1P suppresses IL-1- and TNFα- induced mRNA expression of IP-10 and
RANTES in several cell types.
Since S1P suppressed IL-1-induced IP-10 and RANTES mRNA expression in
astrocytes, we analyzed whether this inhibition was astrocyte- and IL-1-specific.
Interestingly, S1P also quenched IL-1 stimulated IP-10 and RANTES mRNA expression in
U373 glioblastoma, HeLa, and mouse embryonic fibroblasts (MEFs) (Figure 3.3 A, B, and
C). The fold activation of IP-10 and RANTES mRNA expression by IL-1 was significantly
lower, which is likely due to the higher basal mRNA expression of IP-10 and RANTES in
these cells. As IL-1α and IL-1β have similar signaling (ref. in ), we stimulated astrocytes
with IL-1β and S1P to confirm that S1P can also inhibit IL-1β signaling. Indeed, IL-1α and
IL-1β similarly activated IP-10 and RANTES mRNA expression, and S1P suppressed IL-1β
as efficiently as IL-1α (Figure 3.4 A and B). Furthermore, we investigated whether S1P can
also inhibit TNFα-induced chemokine mRNA expression. In fact, S1P quenched TNFα
induced mRNA expression of both IP-10 and RANTES (Figure 3.5 A and B), thus
suggesting a common mechanism of inhibition. It is important to note, that recombinant
cytokines may contain trace amounts of LPS, which also activates chemokine expression in
various cell types. Although astrocytes do not respond to low doses of LPS, microglia, which
may be a contaminant of an astrocyte culture, are known to be activated by LPS . In order to
verify that the observed chemokine mRNA expression is due to IL-1 stimulation and not
LPS, we
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Figure 3.3 S1P represses IL-1-induced chemokine gene expression in a variety of cell
types. U373 glioblastoma cells, HeLa cells, and mouse embryonic fibroblasts (MEFs) were
stimulated with 10 ng/ml IL-1 and 5 µM S1P for 8 hours (A, B, and C). RNA was isolated,
and analyzed by qPCR using TaqMan technology. The qPCR data were normalized to
GAPDH mRNA, and expressed as a ratio to mRNA levels in untreated cells. The
experiments were performed in triplicate, and a representative is shown.
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Figure 3.4 IL-1α and IL-1β induce IP-10 and RANTES gene expression similarly.
Astrocytes were treated with 10 ng/ml IL-1α and IL-1β, as well as 5 µM S1P (A and B).
RNA was isolated and the expression of IP-10 (A) and RANTES (B) was analyzed by qPCR.
Data were normalized to GAPDH, and expressed as a ratio to mRNA levels in untreated
cells. The experiment was performed in triplicate, and one is shown.
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Figure 3.5 S1P effectively represses TNFα-induced mRNA expression of IP-10 and
RANTES. Primary human astrocytes were stimulated with 10 ng/ml IL-1β, 10 ng/ml IL-1β
derived from human cells, 5 ng/ml TNFα, and 5 µM S1P for 8 hours (A and B). RNA was
analyzed, and subsequently analyzed by qPCR. The data were normalized to GAPDH, and
expressed as a ratio to untreated cells. The experiment was performed in triplicate, and a
representative is shown.
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stimulated astrocytes with IL-1β isolated from human cells, recombinant IL-1α heated with
trypsin, and compared their stimulation of IP-10 and RANTES mRNA expression to the
chemokine activation in response to 100 pg of LPS (10 fold higher than the suspected
amount of LPS in the recombinant cytokines). Importantly, IL-1β expressed in human cells
stimulated IP-10 and RANTES mRNA expression, although to a lesser extent than the
recombinant IL-1β, and S1P still inhibited this stimulation (Figure 3.6 A and B). More
importantly, incubation of recombinant IL-1α with trypsin, significantly reduced the
activation of IP-10 and RANTES mRNA expression, and 100 pg/ml LPS did not stimulate
IP-10 and RANTES mRNA expression at all (Figure 3.6 A and B). These results indicate a
common component of IL-1 and TNFα signaling targeted by S1P to repress IP-10 and
RANTES mRNA expression. This S1P-induced mechanism of inhibition also functions in
several cell types.

3.4.3 Inhibition of IL-1-induced IP-10 and RANTES mRNA expression is specific to
S1P.
In order to determine that the inhibition of IL-1-induced IP-10 and RANTES gene
expression is specific to S1P, we treated cells with sphingosine and LPA, since LPA was
shown to regulate chemokine expression . In fact, the inhibition of IP-10 and RANTES
mRNA expression was exclusive to S1P, as Sph and LPA were relatively ineffective (Figure
3.7 A and B). Furthermore, the effects of both IL-1 and S1P on IP-10 and RANTES mRNA
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expression were dose-dependent. IL-1 activated IP-10 and RANTES mRNA expression at a
concentration as low as .1 ng (Figure 3.8 A and B). More
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Figure 3.6 LPS does not stimulate IP-10 and RANTES mRNA expression in astrocytes.
Primary human astrocytes were stimulated with 10 ng/ml IL-1α, 10 ng/ml trypsinized IL-1α,
100 pg/ml LPS, and 5 µM S1P for 8 hours. RNA was isolated, and the expression of IP-10
(A) and RANTES (B) were analyzed by qPCR. The data were normalized to GAPDH, and
expressed as a ratio to untreated cells. A representative of two separate experiments is
shown.
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Figure 3.7 Repression of IL-1-induced IP-10 and RANTES mRNA expression is specific
to S1P. Astrocytes were stimulated with 10 ng/ml IL-1β, 1 µM S1P, 1 µM LPA, and 1 µM
Sph for 8 hours (A and B). RNA was isolated, and subjected to qPCR analysis. Data were
normalized to GAPDH, and expressed as a ratio to untreated cells. The experiment was
performed two separate times, and a representative is shown.
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Figure 3.8 IL-1 stimulates IP-10 and RANTES mRNA expression at a dose as low as 0.1
ng/ml. Astrocytes were treated with the indicated amounts of IL-1α and 5 µM S1P for 8
hours. Subsequently, RNA was isolated, and the expression of IP-10 (A) and RANTES (B)
was analyzed by qPCR. Data were normalized to GAPDH, and expressed as a ratio to
untreated cells. The experiment was performed in triplicate, and a representative is shown.
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Figure 3.9 S1P represses IP-10 and RANTES mRNA expression at a concentration as
low as 10 nM. Primary human astrocytes were treated with 10 ng/ml IL-1α, and the
indicated amounts of S1P for 8 hours (A and B). RNA was isolated, and analyzed by qPCR.
Data were normalized to GAPDH, and expressed as a ratio to untreated cells. The
experiment was performed twice, and a representative is shown.
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importantly, S1P suppressed IP-10 and RANTES mRNA expression at a concentration as
low as 10 nM (Figure 3.9 A and B). These results suggest that S1P likely inhibits IP-10 and
RANTES via a receptor mediated-mechanism.

3.4.4 S1P repression of IL-1-stimulated IP-10 and RANTES mRNA expression is
receptor and Gi mediated.
Most of the known effects of S1P are mediated via the G protein-coupled receptors .
Thus we first established that S1P1-3 are expressed by astrocytes, while S1P4 was not present
in these cells and S1P5 was minimally expressed (Figure 3.10), which is in agreement with
previously published results . Subsequently, it was important to identify which of the S1P
receptors mediates the suppression of IL-1-stimulated IP-10 and RANTES mRNA
expression. Consequently, we utilized pharmacological inhibitors (pertussis toxin (PTX),
JTE-013, and VPC23019), since specific siRNA to each receptor could not be used due to
the subsequent interferon response, which stimulates both IP-10 and RANTES mRNA
expression . First, we utilized pertussis toxin (PTX), which inhibits the Gi protein that
couples to all S1P receptors. PTX significantly reduced the inhibition of IP-10 by S1P, while
it almost completely reversed the inhibition of IL-induced RANTES mRNA expression by
S1P (Figure 3.11 A and B). Interestingly, the VPC23019 inhibitor, which at a concentration
of 10 µM inhibits both S1P1 and S1P3, was ineffective at blocking S1P suppression of IP-10
and RANTES mRNA expression (Figure 3.12 A and B). Conversely, the JTE-013 inhibitor,
which blocks S1P2 signaling, was successful in blocking S1P inhibition of the two
chemokines (Figure 3.12 A and B).
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Figure 3.10 S1P receptor mRNA expression in primary human astrocytes. RNA from
untreated primary human astrocytes was analyzed by qPCR using TaqMan technology. The
mRNA expression of S1P1, S1P2, and S1P3 were normalized to GAPDH, and expressed as a
ratio relative to S1P1 expression. Primer efficiencies were calculated, and S1P1 primer
efficiency was similar to that of S1P2 and S1P3. S1P4 was not expressed, and expression
levels of S1P5 are approximately 10,000 times less than those of S1P1, S1P2, and S1P3.
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Figure 3.11 PTX blocks the S1P mediated suppression of IP-10 and RANTES mRNA
expression. Astrocytes were treated with 200 ng/ml pertussis toxin (PTX) overnight.
Subsequently, astrocytes were stimulated with 10 ng/ml of IL-1 or 1 µM S1P for 8 hours.
RNA was isolated, and the expression of IP-10 (A) and RANTES (B) was analyzed by
qPCR. The data were normalized to GAPDH mRNA, and expressed as a ratio to mRNA
levels in untreated cells. The experiment was performed in duplicate, and a representative is
shown.
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Figure 3.12 S1P2 mediates S1P-induced repression of IP-10 and RANTES mRNA
expression. Astrocytes were treated with 1 µM JTE-013 (inhibits S1P2) and 10 µM
VPC23019 (inhibits S1P1 and S1P3) for 30 minutes prior to stimulation with 10 ng/ml IL-1
and 100 nM S1P for 8 hours. RNA was isolated, and analyzed by qPCR. The expression of
IP-10 (A) and RANTES (B) was normalized to GAPDH, and expressed as a ratio to mRNA
in untreated cells. A representative of five separate experiments is shown.
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Together, these results indicate that S1P suppression is mediated by S1P2, and is pertussis
toxin sensitive.

3.4.5 Inhibition of IP-10 and RANTES mRNA expression by S1P is not mediated via
NF-κB.
Since the NF-κB binding sites within both the IP-10 and RANTES promoters play an
important role in their activation , and IL-1 stimulates NF-κB, we investigated whether S1P
could inhibit the activation of NF-κB by IL-1. Accordingly, we analyzed the degradation of
the inhibitor of NF-κB (IκBα), and the phosphorylation of IKKα/β, which is the kinase that
phosphorylates IκBα. S1P weakly induced both the phosphorylation of IKKα/β, and the
degradation of IκBα. In addition, IL-1 substantially stimulated IKKα/β phosphorylation and
IκBα degradation (Figure 3.13 A and B). More importantly, S1P, in conjunction with IL-1,
neither inhibited the IL-1-induced phosphorylation of IKKα/β, nor the degradation of IκBα.
Moreover, an NF-κB reporter, containing three NF-κB sites fused to the tk promoter was
stimulated by both S1P and IL-1 alone, and their effects were additive when used
concomitantly (Figure 3.14). These data clearly demonstrate that S1P can not inhibit NF-κB
activation. We further verified these findings using the pharmacological inhibitor of IKKα/β,
Bay11-7082. This inhibitor significantly reduced the IL-1-induced mRNA expression of
IP-10 and RANTES; however, it did not block the inhibitory properties of S1P (Figure 3.15
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A and B). In accordance with these results, the proteasome inhibitor, MG-132, totally
abolished IL-1
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Figure 3.13 S1P and IL-1 stimulate components necessary for activation of NF-κB.
Astrocytes were stimulated with 5 µM S1P and 10 ng/ml IL-1 for the indicated times. The
cell lysates were prepared, and analyzed by Western blotting with anti-IκBα and antiphospho-IKKα/β (A, B). The blots were stripped and re-probed with anti-tubulin antibodies
to insure equal loading and transfer (A, B).
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Figure 3.14 NF-κB reporter construct is activated by S1P and IL-1. Astrocytes were
transiently transfected with the NF-κB-Luc reporter. Subsequently, cells were stimulated
with 10 ng/ml IL-1 and 5 µM S1P for 8 hours. Cell lysates were collected, and luciferase
activity was measured. The luciferase activity was normalized to β-galactosidase. A
representative of three separate experiments is shown.
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Figure 3.15 Bay11-7082 significantly reduces IL-1-induced IP-10 and RANTES mRNA
expression. Astrocytes were treated with 5 µM of the Bay11-7082 inhibitor for 1 hour prior
to stimulation with 10 ng/ml IL-1 and 5 µM S1P for 8 hours. RNA was isolated, and qPCR
analysis was performed. The mRNA expression of IP-10 (A) and RANTES (B) was
normalized to the mRNA expression of GAPDH, and expressed as a ratio to mRNA in
untreated cells. The experiment was performed twice, yielding similar results, and one is
shown.

101

102

Figure 3.16 Proteasome inhibition by MG-132 abolishes IL-1-induced mRNA
expression of IP-10 and RANTES. Astrocytes were treated with 15 µM MG-132 inhibitor
for 1 hour prior to stimulation with 10 ng/ml IL-1 and 5 µM S1P for 8 hours. RNA was
isolated, and the mRNA expression of IP-10 (A) and RANTES (B) was analyzed by qPCR.
The data were normalized to GAPDH mRNA, and expressed as a ratio to mRNA levels in
untreated cells. A representative result of two separate experiments is shown.
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stimulation of IP-10 and RANTES mRNA expression (Figure 3.16 A and B). These results
indicate that while NF-κB expression is absolutely necessary for IP-10 and RANTES mRNA
expression in response to IL-1, NF-κB is not responsible for the inhibitory action of S1P.

3.4.6 S1P and IL-1 activate multiple signaling pathways.
Given that NF-κB activation by IL-1 is not suppressed by S1P, we investigated other
pathways known to be activated by IL-1. Primary human astrocytes were stimulated with
S1P and IL-1 for a series of short time points, and the protein expression of total TAK1,
phophorylated c-Jun, phosphorylated JNK, phosphorylated p65, and phosphorylated ATF2
were analyzed (Figure 3.17). We discovered that S1P did not have an adverse affect on any
of the IL-1-induced signaling pathways analyzed. However, it was further confirmed that
NF-κB is enhanced by S1P, and that S1P does not inhibit the IL-1-induced phosphorlyation
of NF-κB.

3.4.7 S1P blocks the IL-1-induced mRNA expression of IFNβ, and the phosphorylation
of STAT1 and STAT2.
In addition to NF-κB binding sites, both the IP-10 and RANTES promoters possess
ISRE binding sites, which bind the STAT1/STAT2/IRF9 heterotrimer . In addition, the IP-10
promoter contains a GAS element that binds STAT1/STAT1 homodimers . Since STAT1
and STAT2 are important for the regulation of both IP-
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Figure 3.17 S1P and IL-1 stimulate multiple signaling pathways. Astrocytes were
stimulated with 10 ng/ml IL-1 and 5 µM S1P for the indicated times. Cell lysates were
prepared, and subjected to Western blot analysis using anti-phospho-c-Jun, anti-phosphop65, anti-phospho-JNK, anti-phospho-ATF2, and anti-TAK1. The blots were stripped and
re-probed using anti-tubulin antibodies to ensure equal loading and transfer.
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Figure 3.18 S1P abolishes IL-1-induced phosphorylation of STAT1 and STAT2.
Astrocytes were stimulated with 10 ng/ml IL-1 and 5 µM S1P for the indicated times. Cell
lysates were prepared, and analyzed by Western blotting using anti-phospho-STAT1 and
anti-phospho-STAT2. Blots were stripped and re-probed using anti-tubulin antibodies to
ensure equal loading and transfer.
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10 and RANTES mRNA expression, the phosphorylation of STAT1 and STAT2 was
analyzed in response to S1P and IL-1 (Figure 3.18). IL-1 efficiently stimulated the
phosphorylation of STAT1 and STAT2 at 4 and 8 hours, but co-treatment with S1P
completely abolished this phosphorylation. Since STAT1 and STAT2 phosphorylation is
induced by interferon, we examined the mRNA expression of IFNβ in response to IL-1 and
S1P (Figure 3.19). Indeed, IL-1 induced low levels of IFNβ (approximately a 10 fold
increase); however, S1P almost completely blocked this induction. In agreement with these
results, inhibition of new protein synthesis, by cycloheximide (CHX), eliminated IL-1
induced IP-10 mRNA expression (Figure 3.20 A). In contrast, CHX enhanced RANTES
mRNA expression, as has previously been reported (Figure 3.20 B). To further substantiate
the hypothesis that S1P inhibits IP-10 and RANTES up-stream of IFNβ production,
astrocytes were stimulated with S1P in conjunction with IFNα, IFNβ, and IFNγ (Figure 3.21
A, B, C, and D). In contrast to S1P-mediated inhibition of IL-1- and TNFα-induced IP-10
and RANTES mRNA expression, S1P enhanced IFNα, IFNβ, and IFNγ activation of IP-10
and RANTES mRNA expression. Nevertheless, IFNγ was ineffective in inducing RANTES
mRNA expression, which is most likely due to the fact that IFNγ is only capable of
stimulating STAT1/STAT1 homodimer formation, and RANTES lacks the GAS element
that binds STAT1/STAT1 homodimers. Taken together, these results suggest that S1P
suppresses IP-10 and RANTES mRNA expression via the inhibition of IL-1-induced IFNβ
mRNA expression, and thus the subsequent STAT1 and STAT2 phosphorylation necessary
for IP-10 and RANTES activation.
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Figure 3.19 S1P represses IL-1-induced IFNβ mRNA expression. Astrocytes were
stimulated with 10 ng/ml IL-1 and 5 µM S1P for 3 hours. RNA was isolated, and the mRNA
expression of IFNβ was analyzed by qPCR. The mRNA expression was normalized to
GAPDH mRNA, and expressed as a ratio to untreated cells. A representative result from four
separate experiments, which produced similar results, is shown.
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Figure 3.20 New protein synthesis is required for IL-1-induced mRNA expression of
IP-10. Astrocytes were treated with 20 µg/ml cycloheximide (CHX) for 1 hour prior to
stimulation with 10 ng/ml IL-1 and 5 µM S1P for 8 hours. RNA was isolated, and analyzed
by qPCR. The mRNA mRNA expression of IP-10 (A) and RANTES (B) was normalized to
GAPDH mRNA, and expressed as a ratio to untreated cells. The experiment was performed
twice, and a representative is shown.
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Figure 3.21 S1P synergizes with exogenous IFN to stimulate IP-10 and RANTES
mRNA expression. Astrocytes were stimulated with 1000 u/ml IFNα, IFNβ, and IFNγ, as
well as 5 µM S1P for 8 hours. RNA was isolated, and analyzed by qPCR. The mRNA
mRNA expression of IP-10 (A) and RANTES (B) was normalized to GAPDH mRNA, and
expressed as a ratio to untreated cells. The experiment was performed in triplicate, and a
representative is shown.
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3.4.8 TAK1 is required for S1P inhibition of STAT1 and STAT2 phosphorylation, as
well as IP-10 and RANTES gene expression.
As NF-κB activation is necessary for IL-1-induced IP-10 and RANTES mRNA
expression (Figures 3.15 and 3.16), but not for S1P inhibition, we assessed whether it is
necessary for STAT1 and STAT2 phosphorylation. We stimulated astrocytes with IL-1 and
S1P in the presence of the IKKα/β inhibitor (Bay11-7082), and subsequently analyzed the
phosphorylation of STAT1 and STAT2 (Figure 3.22). Bay11-7082 abolished IL-1-induced
phosphorylation of STAT1 and STAT2. Thus, NF-κB is not only necessary for IP-10 and
RANTES mRNA expression, but also for the IL-1-induced mRNA expression of IFNs,
which leads to the phosphorylation of STAT1 and STAT2. In search for a target of S1P
action, we turned our attention to TAK-1, which is needed for MAPK activation by IL-1 (,
Figure 3.23 B). We used a specific TAK1 inhibitor, which blocks the activation of its
downstream targets, such as JNK and p38 (Figure 3.23 B). Indeed, the TAK1 inhibitor
abolished the inhibitory effect of S1P on IL-1-induced STAT1 and STAT2 phosphorylation
(Figure 3.23 A). More importantly, the TAK1 inhibitor also blocked S1P inhibition of IL-1
stimulation of IP-10 and RANTES mRNA expression (Figure 3.24 A and B). In fact, S1P
synergized with IL-1 in the presence of the TAK1 inhibitor. It is also important to note that
the IL-1-induced mRNA expression of IP-10 and RANTES was significantly reduced by the
TAK1 inhibitor, signifying the importance of TAK1-dependent signaling. These results were
confirmed in TAK1-/- MEFs, which were un-responsive to IL-1 and S1P in regards to IP-10
and RANTES mRNA expression, and the basal level of IP-10 and RANTES mRNA
expression was also significantly impaired in
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Figure

3.22

Inhibition

of

IKKα/β

by

Bay11-7082

abolishes

IL-1-induced

phosphorylation of STAT1 and STAT2. Astrocytes were treated with 5 µM Bay11-7082
inhibitor for 1 hour prior to stimulation with 10 ng/ml IL-1 and 5 µM S1P for 4 hours. Cell
lysates were prepared and analyzed by Western blotting using anti-phospho-STAT1 and
anti-phospho-STAT2. The blots were stripped and re-probed using antibodies to anti-tubulin
to ensure equal loading and transfer.
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Figure 3.23 TAK1 inhibitor reverses S1P suppression of IL-1-induced phosphorylation
of STAT1 and STAT2. Astrocytes were treated with 600 nM TAK1 inhibitor for 3 hours
prior to stimulation with 10 ng/ml IL-1 and 5 µM S1P for 4 hours (A) or 15 minutes (B).
Cell lysates were prepared and analyzed by Western blotting using anti-phospho-STAT1 and
anti-phospho-STAT2 (A), as well as anti-phospho-p38 and anti-phospho-JNK (B). The blots
were stripped and re-probed with anti-tubulin antibodies to ensure equal loading and
transfer.
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Figure 3.24 TAK1 inhibitor blocks S1P suppression of IL-1-induced IP-10 and
RANTES mRNA expression. Astrocytes were treated with 600 nM TAK1 inhibitor for 3
hours prior to stimulation with 10 ng/ml IL-1 and 5 µM S1P for 8 hours. RNA was isolated,
and the mRNA expression of IP-10 (A) and RANTES (B) was analyzed by qPCR. The data
were normalized to GAPDH mRNA expression, and expressed as a ratio to untreated cells.
The experiment was performed in two separate experiments, and one is shown.
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Figure 3.25 mRNA expression of IP-10 and RANTES is completely abolished in
TAK1-/- MEFs. TAK1 WT and TAK1 KO MEFs were stimulated with 10 ng/ml IL-1 and 1
µM S1P for 8 hours. RNA was isolated, and the mRNA expression of IP-10 (A) and
RANTES (B) was analyzed by qPCR. The data were normalized to GAPDH mRNA, and
expressed as a ratio to untreated cells. The experiment was performed in two separate
experiments, and one is shown.
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these cells (Figure 3.25 A and B). These results suggest that TAK1 is necessary for IP-10
and RANTES basal mRNA expression, the IL-1-induced mRNA expression, as well as the
inhibition of STAT1 and STAT2 phosphorylation and IP-10 and RANTES mRNA
expression by S1P.

3.4.9 S1P induces hyper-phosphorylation of TAK1
Since TAK1 appears to be the key to the regulation of IP-10 and RANTES mRNA
expression by S1P and IL-1, we investigated the effect of S1P and IL-1 on the
phosphorylation of TAK1, and several known targets of TAK1 (Figure 3.26). In astrocytes,
IL-1 induced rapid and transient phosphorylation of TAK1 within 15 min, while costimulation with S1P resulted in increased and sustained phosphorylation, lasting up to 2
hours. However, the IL-1-induced phosphorylation of the downstream targets of TAK1,
including JNK, p38, ATF-2, MKK3/6, MKK4, and MKK7 were unaffected by S1P.
Furthermore, the phosphorylation of MEKK1, another MAP3K kinase that is known to
activate JNK , was also unaffected by S1P. These results suggest that S1P, via an unknown
mechanism, specifically induces sustained hyper-phosphorylation of TAK1, which affects
the IL-1-induced mRNA expression of IP-10 and RANTES.
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Figure 3.26 IL-1 and S1P activation of downstream targets of TAK1. Astrocytes were
stimulated with 10 ng/ml IL-1 and 5 µM S1P for the indicated times. Cell lysates were
prepared and the same cell lysates were analyzed by Western blotting using anti-phosphoTAK1 [Thr184/187], anti-IRAK1, anti-phospho-MKK7, anti-phospho-MKK4, anti-phosphoMKK3/6, anti-phospho-MEKK1, anti-phospho-p38, anti-phospho-JNK, anti-phospho-ATF2,
anti-p38, anti-TAK1, and anti-phospho-TAK1 [Ser412] antibodies. Blots were stripped and
re-probed with anti-tubulin antibodies to ensure equal loading and transfer.
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3.4.10 S1P inhibition of IP-10 involves the ISRE binding site within its promoter.
In order to gain insight on the mechanism of S1P-mediated inhibition, we utilized
several human IP-10 reporter constructs in transient transfection experiments in primary
human astrocytes (Figure 3.27). The truncated IP-10 reporter (TGL_IP-10) contains an ISRE
and two NF-κB binding sites, which are known to be important for IP-10 expression .
Indeed, in astrocytes, IL-1 induced the truncated IP-10 reporter, while S1P suppressed this
induction (Figure 3.28 A). Furthermore, mutation of the ISRE site reduced the response to
IL-1, and S1P was not able to inhibit IP-10 reporter activity; while, mutation of the second
NF-κB site simply reduced the basal luciferase activity (Figure 3.28 B and C). Thus, these
results imply that the ISRE site within the IP-10 promoter is crucial for the repression of
IL-1-induced IP-10 mRNA expression by S1P.
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Figure 3.27 Diagram of TGL-IP-10-Luc reporter, as well as the ISRE and κB2 mutants.
pTGL-IP-10 contains the ISRE site, and the two NF-κB sites known to be important for
IP-10 mRNA expression. pTGL-IP-10-ISRE contains a mutation in the ISRE binding site,
and the pTGL-IP-10-κB2 Mut contains a mutation in the second NF-κB site.
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Figure 3.28 The ISRE site within the IP-10 promoter is required for the S1P
suppression of IP-10. Astrocytes were transiently transfected with pTGL-IP-10-Luc, TGLIP-10-ISRE-Luc, TGL-IP-10-kB2 Mut-Luc, and β-galactosidase as a control for transfection
efficiency. One day after transfection, cells were grown in 1% serum overnight.
Subsequently, cells were stimulated with 10 ng/ml IL-1 and 5 µM S1P for 8 hours, and then
lysed. Luciferase activity was normalized to β-galactosidase activity. A representative of
three separate experiments is shown.
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3.5 DISCUSSION
Multiple sclerosis is a disease of the central nervous system characterized by
demyelination and axonal loss, as well as periods of remission and relapse. Demyelination is
caused by an inflammatory response that detaches myelin from neurons, and cells such as
microglia and astrocytes exacerbate the situation by causing glial scarring. This
inflammatory response is primarily attributed to auto-reactive T cells. T cells are attracted to
sites of inflammation by chemokines, which are released by activated microglia and
astrocytes. In particular, two T cell chemotactic chemokines, IP-10 and RANTES, have been
found to be increased within demyelinated lesions of MS patients . Furthermore, antiCXCL10 (IP-10) mAbs, and a RANTES variant (44AANA47-RANTES) both reduce disease
onset and severity . Thus, treatments that target these two chemokines may prove to be
efficacious in treating MS patients.
IL-1, the major pro-inflammatory cytokine of the brain, has been reported to increase
a variety of chemokines, including IP-10 and RANTES, in the brain . Moreover, increased
levels of IL-1 have also been associated with MS lesions . Interestingly, IL-1 also increases
the expression and activity of SphK1, which is the enzyme that produces the bioactive lipid
S1P by the phosphorylation of Sph . Here we show that S1P significantly inhibits IL-1induced IP-10 and RANTES mRNA expression, while augmenting IL-1-stimulated mRNA
expression of IL-6, IL-8, and MIP-1β in primary human astrocytes.
Interestingly, IL-6 and IL-8 are known to be primarily regulated by NF-κB , while
IP-10 and RANTES are primarily regulated by STATs binding to the ISRE sites
(IRF9/STAT1/STAT2 heterotrimer) present in both promoters, and the GAS element (bind
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STAT1/STAT1 homodimer) present in the IP-10 promoter. Here we show that while S1P
activates NF-κB via inducing the phosphorylation of IKKα/β, the degradation of IκBα, and
the phosphorylation of p65, NF-κB is not important for the repression of IP-10 and
RANTES mRNA expression by S1P. However, NF-κB is indispensable for IL-1-stimulated
IP-10 and RANTES mRNA expression, as the Bay11-7082 inhibitor abolishes both the IL-1
induction of theses genes and the IL-1-induced phosphorylation of STAT1 and STAT2. In
contrast to the activation of NF-κB, S1P abolishes IL-1 induced phosphorylation of STAT1
and STAT2. S1P represses IL-1-induced STAT phosphorylation by inhibiting the production
of IFN, which when released from the cells, binds to their cell surface receptors and activates
the JAK/STAT pathway (Figure 3.29 and 3.30). These results indicate that S1P specifically
targets STAT regulated chemokines, such as IP-10 and RANTES, for inhibition, while
enhancing NF-κB dependent genes, such as IL-6 and IL-8.
Furthermore, the inhibition of IP-10 and RANTES mRNA expression by S1P
appears to be a general, non-cell-specific process, as S1P also blocks IL-stimulation of IP-10
and RANTES mRNA expression in MEFs, HeLa, and U373 cells. In addition, the inhibition
by S1P is not cytokine specific, since S1P also quenches IP-10 and RANTES mRNA
expression stimulated by TNFα; thus, suggesting a common mechanism between IL-1 and
TNFα. This common link is most likely TAK1, as the receptors for IL-1 and
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Figure 3.29 Model of S1P suppression of IL-1-induced IFN mRNA expression. Our
current model is that S1P binds to the S1P2 receptor, and through signaling from its receptor
inhibits IFN mRNA expression at or above the level of TAK1.
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Figure 3.30 Model of S1P repressing IL-1-induced IFN stimulation of IP-10 and
RANTES mRNA expression. IL-1 induces IFN mRNA expression, IFNs activate the JAKSTAT pathway, and phosphorylated STAT1 and STAT2 bind to the ISRE elements within
the IP-10 and RANTES promoters. However, when S1P is present, it represses IL-1-induced
IFN production, which represses STAT phosphorylation, and thus IP-10 and RANTES
mRNA expression.
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TNFα utilize the MyD88 adaptor protein to activate TAK1. Accordingly, the TAK1
inhibitor abolishes S1P-induced repression of IP-10 and RANTES mRNA expression.
Moreover, the TAK1 inhibitor also blocked S1P inhibition of IL-1-stimulated STAT
phosphorylation. Since stimulation with exogenous IFN synergizes with S1P to stimulate
IP-10 and RANTES mRNA expression, it appears that S1P is regulating TAK1 up-stream of
IFN

production.

Furthermore,

S1P

enhances

and

prolongs

endogenous

TAK1

phosphorylation by IL-1. This suggests that S1P may modify TAK1 in such a way that it
fails

to

dissociate

from

the

TRAF6/IRAK

complex,

and

therefore,

becomes

hyperphosphorylated by IRAK.
In conclusion, our data indicate that S1P specifically targets T cell chemokines, IP-10
and RANTES, while increasing neutrophil and macrophage chemokines, such as IL-8 and
MIP-1β, as well as IL-6. In addition, inhibition by S1P occurs via a general mechanism that
leads to the inhibition of IFN production, and the subsequent STAT1 and STAT2
phosphorylation. Due to the fact that the major pathology of MS is due to autoreactive T
cells infiltrating the brain and causing inflammation induced demyelination, a treatment
harnessing the T cell inhibitory effects of S1P would prove to be successful in MS treatment.
In fact, the S1P analog FTY720, which when phosphorylated by SphK2 in vivo is an
effective S1P receptor agonist (for S1P1, S1P3, S1P4, and S1P5) , reduces the rate of
recurrence and gadolinium-enhanced (Gd (+)) lesions in MS patients during phase II clinical
trials, and is currently in phase III trials . However, the exact mechanism of FTY720
mediated suppression of MS recurrence is not yet known. Therefore, as FTY720 mimics
S1P, we propose that the mechanism described here of S1P suppression of IL-1-induced
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IP-10 and RANTES mRNA expression, may be similar to that utilized by FTY720 to reduce
MS lesions.
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CHAPTER 4
GENERAL DISCUSSION AND FUTURE DIRECTIONS

Chronic inflammation within the brain incites multiple CNS diseases, including MS,
Alzheimer’s, Parkinson’s, HIV-associated dementia, and even tumors . The glial cells,
namely microglia and astrocytes, are the main culprits of inflammation within the brain, and
thus CNS disease progression. Although, resting astrocytes are crucial for normal brain
functions, such as secreting neurotrophic factors, glutamate consumption, and functioning as
a necessary component of the BBB . Microglia are not only important for immune
surveillance, but also for programmed removal of neural cells during embryonic
development . However, upon injury or immunological insult, astrocytes and microglia
become activated, and secrete a multitude of pro-inflammatory factors, such as cytokines and
chemokines, cytotoxic factors such, as nitric oxide, and form glial scars that obstruct axonal
regeneration .
IL-1 is the major pro-inflammatory cytokine in the brain, and is released from
activated microglia and astrocytes. IL-1 stimulation of astrocytes has been shown to incite
proliferation

and astrogliosis . Moreover, IL-1 stimulation leads to the expression of

cytokines, such as IL-6 and TNF-α, chemokines, including MIP-1α, MIP-1β, MCP-1, IL-8,
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IP-10, and RANTES (Chapter 3), growth factors, consisting of bFGF, NGF, VEGF, and
PDGF, and matrix metalloproteinases, specifically MMP9 . In addition to MMPs, IL-1 also
increases the expression of the components of another matrix remodeling system, the
plasminogen activator system .
The plasminogen activator system is comprised of two activators uPA and tissue
tPA, and their inhibitors PAI-1, 2, and 3, and the uPA receptor, uPAR. uPA, which when
bound to uPAR attains its own protease activity, and tPA (which is primarily found in the
blood as a clot dissolving enzyme) convert inactive plasminogen into plasmin, which is a
serine protease with a broad range of specificity. IL-1 activation of these matrix remodeling
proteases is significant, since high levels of IL-1 have been shown to be secreted by tumor
cells, such as glioblastoma . Glioblastoma multiforme is the most invasive primary brain
tumor, and as a result all of the current treatments are unsuccessful.
To establish a link between glioblastoma invasion and increased expression of the
components of the plasminogen activator system, we investigated the mRNA and protein
expression of uPAR and PAI-1 in glioblastoma cells upon stimulation with IL-1 (Chapter 2).
In addition, since IL-1 is known to stimulate the expression and activity of SphK1, the
enzyme that produces S1P, we also studied the effects of S1P on the components of the
plasminogen activator system. We found that S1P and IL-1 additively increased the mRNA
expression of uPAR and PAI-1, while uPA was unaffected. Furthermore, S1P and IL-1
increased the in vitro invasion of U373 cells, which was abolished in the presence of siRNA
to PAI-1 and uPAR. This suggests a direct connection between expression levels of both
uPAR and PAI-1 and the invasion of glioma cells. Interestingly, increased levels of PAI-1
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and SphK1 are indicators for a poor prognosis of survival for glioblastoma patients .
Therefore, increased levels of IL-1, and thus SphK1 and S1P, increase the expression of
matrix remodeling proteases, and thereby increase the invasion of glioblastoma cells.
While the roles of S1P, and IL-1, in cancer progression are well-established, the roles
that S1P may play in other CNS diseases, such as MS, are unexplored. Conversely, IL-1 is a
well known instigator and promoter of MS. In fact, increased levels of IL-1 expression have
been found in MS lesions , chronic exposure to IL-1 can lead to demyelination in rat, and
inhibiting IL-1 can reduce the disease in animals . Moreover, IL-1 has been shown to
increase the expression of a variety of chemokines, which then recruit immune cells to the
sites of inflammation. Specifically, IL-1 has been shown to increase the mRNA expression
of IP-10 and RANTES, two T cell chemotactic chemokines. T cells are responsible for the
major pathology of MS, and levels of RANTES and IP-10 are elevated in MS lesions . Since
IL-1 is also known to increase the expression of SphK1, and its product S1P has never been
studied in regards to MS, we investigated the effect of S1P on IL-1-induced IP-10 and
RANTES mRNA expression in primary human astrocytes (Chapter 3). S1P significantly
repressed IL-1 stimulated IP-10 and RANTES mRNA expression, while synergistically
increasing IL-1-induced IL-8, IL-6, and MIP-1β mRNA expression. The obvious
discrepancy in the regulation of these two sets of chemokines/cytokines by S1P is likely due
to their promoter regulation. Indeed, the expression of both IL-8 and IL-6 is NF-κB
dependent, while the expression of RANTES and IP-10 is known to be primarily regulated
by STATs. Interestingly, S1P activates NF-κB, but inhibits the IL-1-induced
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phosphorylation of STAT1 and STAT2 by preventing the production of IFNβ. Moreover,
S1P induces the prolonged hyperphosphorylation of TAK1. These results indicate a
mechanism by which S1P effectively inhibits the mRNA expression of two potent T cell
chemokines, IP-10 and RANTES. Since IP-10 and RANTES are known to promote the onset
and progression of MS , treatments mimicking the inhibitory effects of S1P may prove to be
therapeutic for MS patients.
Currently, an oral S1P receptor agonist (for all S1P receptors except S1P2), FTY720
(Fingolimod), reduces the rate of recurrence and gadolinium-enhanced (Gd (+)) lesions in
MS patients during phase II clinical trials, and is currently being evaluated in phase III
trials . FTY720 is active (FTY720-P) when phosphorylated by SphK2 in vivo , and FTY720P then binds to and causes the internalization, degradation, and decreased mRNA expression
of the S1P receptors . Its effects on MS lesions have been credited to the arrest of T- and Blymphocytes in secondary lymph nodes by FTY720 internalization of the S1P1 receptor .
However, FTY720 easily crosses the BBB, and collects in the brain parenchyma ; thus, it has
been proposed that FTY720 exerts its affects beyond the immune system, and may play a
neuro-protective role . Indeed in EAE models, FTY720-P decreases permeability of the BBB
and affects glial repair mechanisms, which restores nerve function . In addition, FTY720-P
reduces the expression of pro-inflammatory cytokines and chemokines . However, the
precise mechanism of FTY720 mediated suppression of MS lesions is not yet known.
Therefore, we propose that the FTY720 mediated suppression of chemokines and MS lesions
may function by a similar mechanism to that of S1P. Furthermore, treatment with FTY720
can also result in several adverse side effects, including diarrhea, nasopharyngitis,
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bradycardia, and clinically asymptomatic increased levels of liver enzymes ; thus, S1P may
be a natural alternative for treatment of MS.
Nevertheless, the most fascinating questions revolve around the regulation of IFNβ
by S1P. Specifically, since S1P effectively inhibits the production of IFNβ in response to
IL-1, it may also suppress the production of IFN in response to infection with a virus.
Moreover, it raises the possibility that a virus exists that either expresses SphK, or activates
endogenous SphK to block host induction of IFN. Furthermore, S1P is anti-apoptotic and a
well known promoter of cancer progression and metastasis, but could the anti-apoptotic
effects of S1P be related to its inhibitory effect on the pro-apoptotic IFN? Given that S1P
also represses chemokine induction in response to TNFα, it may be of interest to further
investigate this mechanism of regulation; although it seems likely that the S1P regulation of
TNFα involves the same, or a similar mechanism to that of IL-1. However, all of these
questions remain to be investigated in future projects. Meanwhile, this dissertation expands
on the existing knowledge that IL-1 and S1P increase the mRNA and protein expression of
uPAR and PAI-1, and that this increase in expression is associated with an increase in
glioma cell invasion. Moreover, this thesis describes a novel mechanism by which S1P
inhibits IL-1-induced IP-10 and RANTES mRNA expression. Thus, this dissertation
identifies new thearapeutic targets for two devastating CNS diseases, glioblastoma and
multiple sclerosis.
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APPENDIX A
REGULATION AND FUNCTIONS OF SPHINGOSINE KINASE IN THE BRAIN

A.1 ABSTRACT
It has long been known that sphingolipids, especially sphingomyelin, a principal
component of myelin, are highly enriched in the central nervous system and are structural
components of all eukaryotic cell membranes. In the last few years, substantial evidence has
accumulated from studies of many types of cells demonstrating that in addition to their
structural roles, their breakdown products form a new class of signaling molecules. with
potent and myriad regulatory effects on essentially every cell in the body. While the
sphingolipid metabolites sphingosine and its precursor ceramide have been associated with
cell growth arrest and apoptosis, sphingosine-1-phosphate (S1P) enhances proliferation,
differentiation, and cell survival as well as regulates many physiological and pathological
processes. The relative levels of these three interconvertible sphingolipid metabolites, and
thus cell fate, are strongly influenced by the activity of sphingosine kinases, of which there
are two isoforms, designated SphK1 and SphK2, the enzymes that phosphorylate
sphingosine to produce S1P. Not much is yet known of the importance of S1P in the central
nervous system. Therefore, this review is focused on current knowledge of regulation of
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SphK1 and SphK2 on both transcriptional and posttranslational levels and the functions of
these isozymes and their product S1P and its receptors in the central nervous system.
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A.2 INTRODUCTION
The interconvertible sphingolipid

metabolites,

ceramide,

sphingosine,

and

sphingosine-1-phosphate (S1P), are now recognized as important bioactive mediators that
regulate many cellular and physiological processes . To highlight just a few of these,
ceramide and sphingosine have been shown to be involved in cell cycle arrest and apoptosis ,
while S1P has been implicated in cell proliferation, survival, migration, angiogenesis, and
differentiation . The relative levels of ceramide and sphingosine compared to S1P, also
known as the sphingolipid rheostat, is critical in determining cell fate . Thus, increased levels
of S1P can protect against apoptosis mediated by increases in cellular ceramide, a major
response to stress . The synthesis and metabolism of sphingolipids was recently discussed in
an excellent review and will not be discussed here. However these pathways are shown in
Figure A.1 and the reader is referred to this comprehensive review for detailed information.
S1P can act intracellularly to increase DNA synthesis and suppress apoptosis and regulate
calcium mobilization , although the intracellular targets of S1P are still elusive. The most
well-characterized functions of S1P are mediated by binding to five ubiquitously expressed
G protein-coupled receptors (named S1P1-5) . The S1P receptors couple to a variety of G
proteins with varying affinities for different effector molecules that activate numerous
downstream signaling pathways . Thus, depending on the spectrum of S1P receptors
expressed in a given cell type, S1P can activate various pathways regulating numerous
important cellular and physiological functions . Sphingosine kinases (SphKs), the enzymes
that produce S1P by phosphorylating sphingosine, are essential elements in the regulation of
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Figure A.1 Abbreviated model showing pathways for production and synthesis of S1P, and
its actions through S1P receptors expressed in the brain.
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S1P levels, and hence levels of its precursors, sphingosine and ceramide. There are two
isoforms of SphK, SphK1 and SphK2, that have different properties and subcellular
locations , suggesting that they have distinct biological functions, although they may be able
complement each other for some vital functions since production of S1P is critical for brain
and cardiovascular system development . Many studies have established that expression of
SphK1 is associated with cell survival and proliferation. Presumptive evidence suggests that
sphk1 may be an oncogene: overexpression of SphK1 in NIH 3T3 cells enhances foci
formation, colony growth in soft agar, and tumor formation in SCID mice ; MCF7 human
breast cancer cells overexpressing SphK1 produce larger and more abundant tumors in
xenografts ; and SphK1 is expressed at high levels in many types of cancers . The biological
functions of SphK2 are not yet clearly defined and appear to vary depending on the cell type.
However, when overexpressed, SphK2 generally acts as a “bad” kinase and induces cell
cycle arrest and apoptosis . Because there is such a paucity of information on the role of
SphKs and S1P at the molecular level in the central nervous system, this review will first
focus on current knowledge of transcriptional and posttranscriptional regulation of SphKs
gleaned from studies in various types of cells.
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A.3.1 STRUCTURE AND LOCALIZATION OF SPHINGOSINE KINASES
In humans, the sphk1 gene is located on chromosome 17 (17q25.2), while the sphk2
gene is on chromosome 19 (19q13.2). SphK1 and SphK2 are highly homologous and contain
five conserved domains, one of which includes the conserved diacylglycerol kinase ATP
binding domain . Although SphK1 and SphK2 display 80% amino acid sequence similarity ,
they differ in their central regions and N termini. SphK1 lacks transmembrane domains or
identifiable signal sequences and is mainly cytosolic . SphK1 is abundantly expressed in
adult mouse heart, spleen, lung, and brain, whereas SphK2 expression is highest in brain,
kidney, and liver . SphK2 is about 240 amino acids longer than SphK1 at its N terminus and
contains several transmembrane domains . In addition, SphK2 possesses a nuclear
localization signal within its N terminal region, which when mutated, prevents it from
entering the nucleus and inhibiting DNA synthesis . Unlike SphK1, which is mainly
localized to the cytosol in all cells, SphK2 localization is cell type-specific. For example, in
HEK 293 cells, SphK2 can be detected in the plasma membrane, mitochondria, ER, Golgi,
and in the cytosol , whereas, in COS7, HeLa, MCF7, and NIH 3T3 cells, it is predominantly
localized to the nucleus .

A.3.2. ACTIVATION OF SPHINGOSINE KINASES
A broad range of external stimuli has been reported to activate SphK1, among which
are various growth factors including platelet-derived growth factor (PDGF), epidermal
growth factor (EGF), vascular endothelial growth factor (VEGF), nerve growth factor
(NGF), basic fibroblast growth factor (bFGF), transforming growth factor beta (TGFβ), and
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insulin-like growth factor-1 (IGF-1), cytokines such as TNF-α and interleukins, and
hormones (estradiol and prolactin) (reviewed in ). Many of these stimuli activate SphK1 in a
biphasic manner. That is to say, the first phase of activation is rapid (minutes) and transient,
most likely via post-translational modifications that increase enzymatic activity and its
translocation to the plasma membrane where its substrate sphingosine resides, and a second
phase of activation over the next 24 h that entails upregulation of transcription. Much less is
known about regulation of SphK2 activity.

A.3.3. POST-TRANSLATIONAL ACTIVATION OF SPHK1 AND SPHK2
Several SphK1 interacting proteins have been identified by the yeast two-hybrid
approach . Although some have been shown to interact with SphK1 in mammalian cells,
none have yet been implicated in regulation of SphK1 activity or S1P production.
Crosslinking of the high affinity IgE receptor (FcεRI) on mast cells activates SphK1,
increasing production of S1P, which is secreted and regulates mast cell functions in an
autocrine or paracrine manner by binding to S1P receptors. Recently, activation of SphK1
was shown to be due to direct interaction with Lyn tyrosine kinase . This interaction
explicitly enhanced the enzymatic activities of both SphK1 and Lyn, although SphK1 was
not phosphorylated by Lyn. More recently, SphK2 was also reported to be activated upon
FcεRI crosslinking . In addition, Fyn, another Src protein tyrosine kinase, is also essential for
SphK1 and SphK2 activation, since mast cells from Fyn deficient mice exhibit impaired
SphK1 and SphK2 enzyme activity and S1P production . However, neither SphK, nor SphK2
are substrates for Fyn. Rather, activation of SphK1 by Fyn involves the adapter Grb2-
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associated binder 2 and phosphatidylinositol 3-kinase, but activation of SphK2 is
independent of this pathway .
In contrast, some activators require Ca2+ to stimulate SphK. For instance, activation
of SphK1 by platelet derived growth factor BB (PDGF-BB) is blocked by chelation of
intracellular Ca2+ with BAPTA-AM . Specifically, PDGF activation of SphK1 requires
phosphorylation of the PDGF receptor on tyrosine-1021, which is necessary for the
subsequent association with PLCγ, thus leading to production of InsP3 and downstream
mobilization of calcium . Moreover, it has been proposed that SphK1 contains several
putative Ca2+/calmodulin binding sites . In agreement, translocation of SphK1 to the plasma
membrane induced by the PKC activator phorbol ester is inhibited by the loss of the
functional calmodulin binding site . In spite of these findings, direct activation of SphK1 by
Ca2+ or calmodulin has not been detected.
EGF is one of the most potent, and most well studied, activators of SphK1. In MCF7
cells, EGF stimulates SphK1 activity and induces its translocation from the cytosol to the
plasma membrane . A novel EGF pathway involving sequential activation of c-Src, PKCδ,
and subsequent activation and translocation of SphK1 to the plasma membrane was recently
described in glioblastoma cells . Several lines of evidence suggest that PKCδ and SphK1
may be downstream targets of EGF-activated c- Src in these glioma cells: (i) EGF induced
rapid phosphorylation and translocation of PKCδ to the plasma membrane, which was
blocked by the Src inhibitor PP2; (ii) EGF also induced translocation of SphK1 to the plasma
membrane which was blocked by inhibition of c-Src and by downregulation of PKCδ; and
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(iii) downregulation of PKCδ and SphK1 abolished EGF-induced plasminogen activator
inhibitor-1 (PAI-1) expression. It is important to note that although, the high expression of
EGFR alone is not a prognostic marker in gliomas, patients expressing high levels of both
EGFR and PAI-1 have a shorter overall survival prognosis . Thus, our recent results suggest
that SphK1 is a downstream target of PKC. that is indispensable for PAI-1 upregulation by
EGF, and might have important implications for glioma invasiveness. Interestingly, in
primary cytotrophoblasts, the PI3K inhibitor LY294002 blocked EGF-stimulated SphK1
activity, indicating the possible involvement of the PI3K/Akt pathway . Altogether, these
studies suggest that EGF might utilize diverse signaling pathways to rapidly enhance SphK1
activity. Additionally, EGF induced sustained activation of SphK1 that lasted for 24 hours.
Similar sustained activation of SphK1 was also described in both primary human fibroblasts
and in WI-38 fibroblasts in response to TGFβ, suggestive of an increase in transcription .
NGF and bFGF also incite persistent activation of SphK1 in pheochromocytoma PC12 cells;
however, EGF and IGF-1 only transiently stimulate SphK1 in these cells . Moreover, NGF
instigates translocation of SphK1 to the plasma membrane and local production of S1P,
which differentially activates the S1P1 and S1P2 receptors . While the precise mechanism of
SphK1 activation by NGF is still not known, it is mediated by the TrkA tyrosine kinase
receptor for NGF , which activates the Ras/ERK, PI3K/Akt, and PLCγ pathways . In T24
bladder tumor cells, activation of the tyrosine kinase VEGF receptor by VEGF, a potent proangiogenic growth factor, induces phosphorylation and activation of PKC via Flk-1, which
in turn transiently activates SphK1 by direct phosphorylation .
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The protein kinase C activator, phorbol 12-myristate 13-acetate (PMA), also has
been shown to transiently stimulate SphK1 by inducing PKC-dependent phosphorylation and
translocation to the plasma membrane . Furthermore, stimulation of SphK1 by PMA, as well
as the pro-inflammatory cytokine TNF-α, requires its phosphorylation on Ser225 . SphK1
possesses a docking site for ERK1/2 and both ERK1 and ERK2 phosphorylate SphK1 at
Ser225 , which is crucial for its translocation to the plasma membrane . This translocation is
also important for its oncogenic signaling [41]. TNFα, and interleukin-1β (IL-1β) have also
been shown to transiently increase SphK1 enzyme activity in A549 epithelial lung carcinoma
cells . This activation does not stem from increases in its mRNA or protein levels; therefore,
it is most likely due to a phosphorylation event similar to that described above.
As SphK1 has been identified as an important pro-survival factor, it seems logical
that its activity or expression might be regulated by other pro-survival components. One of
these is Bcl-2 which was initially described as an oncogene in follicular lymphomas , and
later found to be an anti-apoptotic protein that promotes cell survival . Interestingly, Bcl-2
expression protects SphK1 from proteolysis induced in response to DNA damaging drugs .
Additionally, overexpression of Bcl-2 in A-375 human melanoma cells increased SphK1
enzyme activity, as well as its expression . Of note, SphK1 mediates BCR/ABL-induced
upregulation of another anti-apoptotic protein Mcl-1 in chronic myeloid leukemia cells. In
these cells, SphK1 expression and activity are upregulated by BCR/ABL via the ERK1/2,
PI3K, and JAK2 pathways . A novel “criss-cross” transactivation mechanism important for
proliferation that involves activation of SphK1 by 17β-estradiol (E2) has also been reported .
In MCF7 human breast cancer cells, E2 binding to the estrogen receptor activates SphK1 and
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increases S1P production. Subsequently, S1P is secreted and signals through the S1P3
receptor to increase metalloproteinase activity and production of EGF which then activates
the EGF receptor . More recently, the hormone prolactin as well as E2 were also reported to
biphasically activate SphK1 in MCF-7 cells . The initial activation of SphK1 occurred
rapidly after stimulation, followed by a much later increase in mRNA and protein expression
and both phases of activation were ablated by MEK and PKC inhibitors . Moreover, the
increase in the proliferation and migration in response to either E2 or prolactin was
significantly reduced by downregulating SphK1 expression, suggesting that activation of
SphK1 is critical for these responses.
Very few studies have examined the mechanism of activation of SphK2. In addition
to activation of SphK2 by crosslinking of FcεRI , EGF-induced activation of SphK2 was
observed in HEK 293 and MDA-MB-453 breast cancer cells . EGF induced migration of
MDA-MB-453 cells was decreased by knock-down of either SphK1 or SphK2, suggesting
that activation of both isozymes by EGF contributes independently to the motility responses
in these cells. In a follow-up study, it was shown that activation of SphK2 induced by EGF
resulted from EGFR-mediated ERK1/2-depenent phosphorylation of SphK2 . Site-directed
mutagenesis indicated that hSphK2 is phosphorylated on Ser351 and Thr578 by ERK1 and
that phosphorylation of these residues is important for EGF-stimulated migration of MDAMB-453 cells .
Lastly, it was recently shown that PMA-induced phosphorylation of SphK2 on a
putative nuclear export sequence (NES) located in the central region of the protein
stimulated CRM1-mediated export from the nucleus to the cytosol . Furthermore, mutation
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of two serine residues (Ser-419 and Ser-421) phosphorylated within this NES-like motif
abolished SphK2 export. Thus, posttranslational modification via phophorylation of SphK2
may be an important regulator of its activity and localization.

A.3.4 TRANSCRIPTIONAL REGULATION OF SPHK1
To date, a great deal of our knowledge of the regulation of the sphk1 gene stems
from studies that were first performed in rodent cells. The rat sphk1 gene contains a 3.7 kb
CpG island, within which there are six transcription start sites, potentially yielding six
alternative first exons; thus indicating that multiple splice variants of the rat sphk1 gene exist
(sphk1a-f) . In the brain, the hypomethylated region of sphk1a is in the 5’ end of the CpG
island, and a tissue-dependent, differentially methylated region (T-DMR) is situated
approximately 800 bp upstream of the sphk1a first exon. The T-DMR is hypomethylated in
the brain, where sphk1a is the sole isoform. In contrast, the T-DMR is hypermethylated in
the heart where sphk1a, as well as the other isoforms, is not expressed. These results suggest
that hypermethylation of the T-DMR is associated with sphk1a suppression. Moreover,
several endogenous antisense transcripts to sphk1, termed Khps1, have also been described .
Of these, Khps1a spans the T-DMR within the CpG island, and its expression induces the
demethylation of CG sites within the T-DMR. Interestingly, the expression of sphk1 or
Khps1 is mutually exclusive, suggesting that the CpG island regulates the intrinsic
expression of sphk1.
Little is known of the regulation of SphK1 expression but several transcription
factors that regulate the sphk1 gene have been identified. The 55-bp fragment localized in
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front of exon 1d mediates NGF induction of sphk1 gene transcription . This fragment
contains one activator protein-2 (AP-2), and two specificity protein 1 (Sp1) binding sites.
Interestingly, the proximal Sp1 site, and not the distal Sp1 site, is required for the intrinsic
expression of the rat sphk1 gene. However, analysis of the 5’ flanking promoter region of the
human sphk1 gene revealed that a 300 bp fragment containing one Sp1 and two AP-2
binding motifs, effectively mediates sphk1 transcription upon PMA treatment in human
megakaryoblastic leukemia MEG-01 cells (Figure A.2) . Moreover, an unknown protein
other than AP-2 binds to the AP-2 binding motifs of the promoter. Furthermore, MEK and
PKC inhibitors also prevented the sphk1 promoter activity induced by PMA. These results
imply that the PMA-induced sphk1 gene expression is mediated by transcription factors that
are activated by the PKC and ERK signaling pathways.
Histamine also upregulates SphK1 expression in endothelial cells via the PKC and
ERK pathways and requires the AP-2 and Sp1 binding motifs of the sphk1 gene . The
importance of these binding motifs in the transcriptional regulation of sphk1 was solidified
by the observations that increased promoter activity induced by prolactin and GDNF also
utilized the AP-2 and Sp1 binding motifs in MCF-7 cells and TGW human neuroblastoma
cells . Moreover, upregulation of SphK1 expression by prolactin also
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Figure A.2 Regulatory elements within the 5’ flanking region of the sphk1 gene. See text
for more details.
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required STAT5 activation, while GDNF induced transcription through the PI3K pathway in
addition to the ERK1/2 pathway.
Subjecting glioma cells to hypoxic stress activates SphK1 and increases its
expression, effects that may be important in more hypoxic areas in the center of a brain
tumor . The increase in SphK1 activity resulted in increased intracellular S1P production and
secretion. Hypoxia is known to enhance stability of hypoxia-inducible factors (HIFs),
transcription factors that bind to hypoxia response elements (HREs) and regulate hypoxiainducible genes (Figure A.2). In this regard, the sphk1 5’ flanking region possesses multiple
putative HRE sites, and a reporter construct containing 3124 bp upstream of the transcription
start site conferred response to hypoxic stress . Furthermore, HIF-1α and HIF-2α both bind
exclusively to a region within the 5’ flanking region that contains an evolutionarily
conserved HRE site. Notably, HIF-2α, and not HIF-1α, activates transcription of the sphk1
gene under hypoxic conditions . In contrast to sphk1, sphk2 transcriptional regulation
remains unexplored.

A.3.5 FUNCTIONS OF SPHINGOSINE KINASES AND S1P IN THE BRAIN
The brain is the organ that contains the highest concentration of S1P . During
pathological conditions, such as brain injury or stroke, local concentrations of S1P may be
further increased as S1P could be released from platelets in blood clots . Moreover, high
expression levels of SphK1 have been correlated with decreased rates of survival for patients
diagnosed with glioblastoma multiforme, the most invasive primary brain tumor . SphK
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activity and S1P also protect cultured mesencephalic neurons against glutamate-induced
neurotoxicity .
There have been contradictory reports as to which SphK isoform is predominantly
responsible for S1P production in normal brain tissue . One study has reported that SphK1 is
the primary isoform in mouse brain , and is highly abundant in the cerebellum where it is
located within the dendrites and dendritic spines of Purkinje cells . As discussed above, it
seems most likely that both SphK1 and SphK2 are expressed in the brain and probably even
within the same cells, as neither of the single SphK knockout mice display a remarkable
CNS phenotype, while the double SphK1-SphK2 knockout mice have a severe brain defect .
A substantial presence of SphK2 in the brain is more consistent with reports on the
effects of the potent immunosuppressant FTY720 in the CNS. It is well established that
FTY720 is phosphorylated in vivo by SphK2, converting it to a S1P mimetic and potent S1P
receptor agonist that accumulates in CNS white matter . In experimental allergic encephalitis
models, FTY720-phosphate affects the blood-brain barrier and glial repair mechanisms,
which restores nerve function . Moreover, FTY720 seems to be a highly promising drug for
treatment of relapsing multiple sclerosis and is currently in Phase III trials .
Thus, clearly both SphK1 and SphK2 must be expressed in the brain, but far more is
known about the functions of SphK1 there. bFGF, another growth factor present in brain,
induced secretion of S1P from cerebellar astrocytes, which was prevented by inhibiting
SphK1 . S1P in turn increased DNA synthesis and activated ERK1/2 via one of its Gi/Go
coupled receptors, of which S1P1, S1P2, and S1P3 are expressed in cerebellar astrocytes. S1P
also signals inside out in hippocampal neurons to facilitate glutamate secretion induced by
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secretagogues and SphK1 may be involved in the underlying regulation of synaptic
transmission . SphK1 is not only capable of regulating functions in the brain via its product
S1P, but also through corresponding effects on intracellular levels of its substrate
sphingosine. Thus, conversion of sphingosine to S1P can also regulate calcium levels in
neurons as sphingosine inhibits voltage-operated calcium channels (VOCC), which prevents
calcium entry in response to depolarization . In agreement, expression of SphK1 in GH4C1
rat pituitary cells reduced inhibition of the VOCC by sphingosine .
An interesting observation was made that SphK1 interacts with and is activated by
neural plakophilin-related armadillo repeat protein (δ-catenin/NPRAP) in hippocampal
neurons . Moreover, a SphK inhibitor decreased δ-catenin/NPRAP-dependent neuronal cell
migration . S1P also plays an important role in motility of glioblastoma cells , and as
previously mentioned, is critical for the process of invasion. Furthermore, S1P signals
through S1P1, S1P2, and S1P3 to stimulate glioma cell proliferation, and activation of S1P1
and S1P3 also amplifies glioma migration and invasion .

A.3.6 S1P RECEPTORS IN THE CNS
Although receptors for S1P are abundant in the central nervous system, only a few
studies have addressed cell-specific functions of S1P via its receptors, and most of these
Table A.1 S1P receptors and functions in neurons and glial cells.

S1P
Receptors

Function in the Brain
Activates neurite outgrowth/extension in neurons

Reference
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S1P1

S1P2

Depolarization-induced glutamate release is dependent
on SphK1, S1P formation, and subsequent S1P1
activation
Migration of neural stem cells toward a site of spinal
cord injury
Mediates stimulation of ERK/Egr-1/FGF-2 in C6 glioma
Mediates ERK activation in astrocytes
Promotes astrocyte motility
Mediates PDGF-induced mitogenesis of
oligodendrocyte precursors
Inhibits neurite extension in neurons
Maintenance of vestibular and cochlear hair cells
Inhibits glioma motility
Increases glioma invasion
Induces morphology changes in C6 glioma cells
Induced PLC/Ca2+ in C6 glioma cells
Essential for neuronal development/excitability in
zebrafish
Spontaneous seizures in S1P2 null mice
Loss of vestibular function in S1P2 null mice
May inhibit neurite extension in PC12 cells

S1P3
Only expressed in lymphatic and hematopoietic tissues

S1P4
S1P5

Stimulation of PLC-Ca2+ and PLD in C6 glioma
Inhibits oligodendrocyte progenitor migration
Induces process retraction and cell survival in
oligodendroglial cells
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have been focused on isolated cells in culture (Table A.1). It has previously been
demonstrated that in PC12 cells and dorsal root ganglion (DRG) neurons, NGF induces
translocation of SphK1 to the plasma membrane . S1P thus causes activation of S1P1 leading
to Rac activation and neurite extension. In addition, NGF downregulates S1P2 and S1P3,
which leads to neurite retraction by activation of Rho . Evidence for the role of S1P in CNS
neuroexcitability emerged from some observations of S1P2 knockout mice. It was noticed
that homozygous knockout mice occasionally exhibited seizure activity characterized
behaviorally by a 2-10 second wild running episode followed by a 15-60 second period of
freezing . These events occurred only in 3-7 week old mice and were accompanied by
changes in electrical activity of the brain . However, recent studies have demonstrated that
S1P2 knockout mice are profoundly deaf from postnatal day 22 and display a progressive
loss of vestibular function .
S1P enhances the excitability of cultured rat DRG neurons that is likely mediated via
S1P receptors, as blockade of G-protein signaling abrogated these effects of S1P . Moreover,
S1P generated intracellularly from ceramide can also increase neuronal excitability by
mechanisms that are poorly understood . S1P was also recently shown to have two actions on
glutamate secretion in primary hippocampal neurons: (i) it can act as a secretagogue to
trigger glutamate secretion and (ii) to potentiate depolarization evoked glutamate secretion .
Depolarization-induced glutamate release was dependent on SphK1, S1P formation, and
subsequent S1P1 activation. These findings indicate that S1P, through its autocrine action,
facilitates glutamate secretion in hippocampal neurons and may be involved in mechanisms
underlying regulation of synaptic transmission . Furthermore, neural stem/progenitor cells
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migrate toward a damaged area of the CNS to reduce the damage. It was recently reported
that S1P concentration in the spinal cord was increased after a contusion injury, due to
accumulation of microglia and reactive astrocytes in the injured area. Moreover, this locally
increased S1P induced migration of transplanted neural stem/progenitor cells through its
receptor S1P1 .
S1P is also involved in growth and survival of oligodendrocytes , the myelinating
cells of the CNS. The survival promoting effect of neuotrophin-3 (NT-3) on oligodendrocyte
precursors was shown to be dependent on SphK1 and S1P itself was able to stimulate CREB
phosphorylation, an important NT-3 survival signaling pathway . S1P5, which is exclusively
expressed on oligodendrocytes and throughout their development, has different functions
depending on the developmental stage. It mediates process retraction of oligodendrocyte
precursors and promotes survival of mature oligodendrocytes . Moreover, activation of S1P5
inhibits oligodendrocyte progenitor migration . S1P receptors are differentially modulated in
oligodendrocyte progenitors by PDGF resulting in downregulation of S1P5 and upregulation
of S1P1 . Moreover, S1P1 is involved in PDGF-induced proliferation of oligodendrocyte
progenitors. Thus, S1P1 and S1P5 may have different functions during oligodendroglial
development, and possibly during remyelination .
Destruction of oligodendrocytes is a key pathological process in multiple sclerosis
(MS). The current therapies available for MS utilize an immunomodulatory approach to
prevent T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and
axonal loss. Recently, the sphingosine analogue, FTY720 (Fingolimod), was shown to
significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials .
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FTY720 is a pro-drug that is phosphorylated in vivo by SphK2 but not SphK1

to

biologically active FTY720-phosphate (FTY720-P), a mimetic of S1P. FTY720-P binds to
four of the five known S1P receptors, but not to S1P2. Although it is a S1P1 receptor agonist,
it has been shown to cause prolonged receptor downregulation . As S1P1 is required for
lymphocytes to sense and move towards the S1P gradient between tissues and blood, its loss
prevents egress of thymocytes and lymphocytes from secondary lymphoid tissues into the
circulation . It has been assumed that the beneficial effects of FTY720 result from
retardation of lymphocyte mobilization to sites of inflammation without an induction of a
generalized state of immunosuppression. However, the mechanisms underlying the action of
FTY720 in MS have not yet been definitively identified. For example, FTY720 has been
shown to also have direct effects on oligodendrocyte progenitors . Treatment of these cells
with FTY720 causes activation of ERK1/2 and Akt, accompanied by protection from
apoptosis . FTY720P also regulates oligodendrocyte progenitor differentiation into mature
oligodendrocytes . However, FTY720 also arrested oligodendrocyte differentiation, an effect
that was counteracted by NT-3, which not only enhanced the survival of oligodendrocyte
progenitors induced by FTY720, but also stimulated their maturation . FTY720 also was
recently shown to induce time-dependent modulation of S1P receptors on human
oligodendrocyte progenitors with consequent functional responses that were directly relevant
for the remyelination process . Altogether, these observations suggest that in addition to its
immunosuppressive functions, FTY720 could also have a beneficial effect in MS by these
direct actions on oligodendrocyte progenitors. However, the finding that FTY720 impedes
the differentiation of these cells raises the question of whether FTY720 therapy for MS
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should include the use of differentiation-enhancing factors, such as NT-3 . This approach
could ensure both protection of existing oligodendrocyte progenitor pools against immunemediated insults as well as stimulation of remyelination by enhancing the maturation of
these cells.
Much less is known of the roles of S1P in other types of glial cells. Astrocytes, the
major type of glial cell in the brain, are another target of FTY720 in the CNS as they express
S1P1, S1P2, and S1P3 . FTY720-P as well as another agonist of S1P1, SEW2871, stimulate
astrocyte migration . Astrocytes also express SphKs and can synthesize S1P and release it
for autocrine/paracrine actions . An interesting finding was that fibroblast growth factor
(FGF), whose synthesis was earlier shown to be increased by S1P , can also stimulate S1P
release from astroglial cells , suggesting a signaling amplification loop that further adds to
the complexity of the relationship between growth factors and S1P. Moreover, S1P is present
at high levels in blood and can enter the brain during CNS injury. Reactive astrogliosis, a
prominent component of CNS injury with potentially harmful consequences, could also
involve S1P-mediated proliferation of astrocytes .
In injured spinal cords, reactive astrocytes and microglia around the injury sites
colocalize to regions with high levels of S1P , suggesting that the accumulation of reactive
astrocytes and microglia after spinal cord injury may be responsible for the increased level of
S1P. Only one study so far has examined functions of S1P and the expression of S1P
receptors in microglia, resident brain macrophages . While S1P1 S1P2, S1P3, and S1P5 were
all expressed by acutely isolated microglia, S1P3 expression was lost after two weeks in
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culture . In addition, stimulation of microglia with S1P induced the release of TNFα,
suggesting the potential involvement of S1P in CNS inflammation .
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A.4 PERSPECTIVES
Knowledge of SphKs and the functions of S1P has grown immensely over the past
several years, and this trend will surely continue. It is truly amazing that so much has been
written about the functions of S1P, yet so little is still known of the regulation of the
enzymes that determine its levels. It is a growing field, with important implications for future
therapeutics for neurodegenerative disorders, particularly MS. Progress in developing
specific agonists and antagonists of S1P receptors, as well as specific inhibitors of SphK1
and SphK2 will provide the necessary tools to understand their functions and development of
new approaches to target the S1P axis.
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